WO2017070516A1 - Prostate-targeting adeno-associated virus serotype vectors - Google Patents

Prostate-targeting adeno-associated virus serotype vectors Download PDF

Info

Publication number
WO2017070516A1
WO2017070516A1 PCT/US2016/058185 US2016058185W WO2017070516A1 WO 2017070516 A1 WO2017070516 A1 WO 2017070516A1 US 2016058185 W US2016058185 W US 2016058185W WO 2017070516 A1 WO2017070516 A1 WO 2017070516A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
seq
capsid protein
raav
transgene
Prior art date
Application number
PCT/US2016/058185
Other languages
French (fr)
Inventor
Guangping Gao
Jianzhong AI
Hong Li
Qiang Wei
Original Assignee
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts filed Critical University Of Massachusetts
Priority to CA3002980A priority Critical patent/CA3002980A1/en
Priority to EP16858324.3A priority patent/EP3364996B1/en
Priority to US15/769,953 priority patent/US11426469B2/en
Publication of WO2017070516A1 publication Critical patent/WO2017070516A1/en
Priority to US17/813,451 priority patent/US20230073187A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Definitions

  • the prostate is an exocrine gland that is crucial to constituting the male reproductive system, and the functions of prostate are similar in the majority of mammals despite anatomical differences.
  • Three types of prostate diseases are the major threats for the health of prostate, i.e., prostatitis, benign prostate hyperplasia (BPH) and prostate cancer. Together, these prostate diseases are severely compromising the life quality and life span of males, especially for the aged male population.
  • BPH benign prostate hyperplasia
  • prostate cancer is the second most diagnosed malignancy and the sixth leading cause for mortality of all cancers in males worldwide.
  • Adeno-associated virus is a single-stranded DNA virus, and recombinant AAV (rAAV) vectors possess many advantages in gene therapy applications, including low immunogenicity and genotoxicity, broad tissue tropism and high transduction efficiency in vivo, and long-term transgene expression.
  • Aspects of the invention are related to the discovery that rAAV vectors comprising capsid proteins having a certain serotype, including, but not limited to, AAV5, AAV6.2, AAV7, AAV8, AAV9, AAVrh. lO, mediate delivery of transgenes to prostate tissue more efficiently than other vectors (e.g. , rAAV vectors comprising other capsid protein serotypes).
  • the disclosure provides a method for delivering a transgene to prostate tissue, the method comprising: administering to prostate tissue of a subject an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
  • the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.10, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
  • the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7. In some embodiments, the capsid protein comprises an amino acid sequence as set forth in SEQ ID NO: 3 or 4. In some embodiments, the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
  • the transgene encodes a gene associated with a prostate disease.
  • the prostate disease is selected from prostatitis, prostate cancer and benign prostate hyperplasia (BPH).
  • the gene encodes a tumor suppressor molecule (e.g. , a tumor suppressor protein or a miRNA that regulates tumor suppression).
  • the gene encodes BCL-2, PTEN, SLC39A1, BRCA1, BRCA2, HPCl, RUNX2, CLCA2, YAPl, MASPIN, LL37, CDKNIB, AR, NKX3.1, CASP9, FKHR, GSK3, MDM2, ERK1/2, PSA, CCND1, ALDOA, Sox4, CD44, and miR34a.
  • the disclosure is based on the discovery that miR34a expression is downregulated in prostate cancer cells.
  • overexpression of miR34a in prostate cancer cells results in decreased cancer cell viability and migration.
  • the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of a nucleic acid comprising a promoter operably linked to a transgene, wherein the transgene encodes miR34a.
  • the transgene comprises or consists of a nucleic acid having a sequence as set forth in SEQ ID NO: 15.
  • the nucleic acid comprises or consists of a nucleic acid having a sequence as set forth in SEQ ID NO: 16.
  • the administration occurs by injection.
  • the injection is not intraperitoneal injection (i.p.).
  • the injection is intrapro state injection.
  • the administration results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells. In some embodiments, the administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
  • the rAAV further comprises two AAV inverted terminal repeats (ITRs), wherein the ITRs flank the transgene.
  • ITRs AAV inverted terminal repeats
  • the AAV ITRs are ITRs of one or more serotypes selected from: AAV2, AAV3, AAV4, AAV5, and AAV6.
  • the subject is a mammal, optionally a human.
  • FIG. 1 shows a graphical depiction of the anatomical structure of mouse prostate and intraprostate injection sites.
  • lxlO 11 GC per injection site of rAAV vectors were delivered into four sites as indicated by the syringes, namely the two lobes of the anterior prostate (AP) and two sites in the dorsal lateral prostate (DLP).
  • SV seminal vesicle.
  • FIGs. 2A-2B show rAAV6.2, 7 and 9 efficiently transduced mouse AP following intraprostate injection.
  • FIG. 2A shows representative fluorescence images of anterior prostate (AP) cryo-sections showing the merge of EGFP native fluorescence and nuclear staining by DAPI following injections of each of 12 rAAV serotypes or PBS. Squared regions indicate the locations of high magnification images shown in (FIG. 2B). Scale bars represent 100 microns.
  • FIG. 2B shows high magnification images of AP cryo-sections following PBS injection or transduction with rAAV6.2 and 7. Scale bars represent 25 microns.
  • FIGs. 3A-3B show rAAV6.2, and 7 efficiently transduced mouse DLP following intraprostate injection.
  • FIG. 3A shows representative fluorescence images of dorsal lateral prostate (DLP) cryo-sections showing the merge of EGFP native fluorescence and nuclear staining by DAPI following injections of each of 12 rAAV serotypes or PBS. Squared regions indicate the locations of high magnification images shown in (FIG. 3B). Scale bars represent 100 microns.
  • FIG. 3B shows high magnification images of DLP cryo-sections following PBS injection or transduction with rAAV6.2 and 7. Scale bars represent 25 microns.
  • FIGs. 4A-4B show rAAV6.2 and rAAV7 efficiently transduced mouse prostate following intraprostate injection.
  • FIG. 4A shows quantification of transduction efficiency in AP (gray bars) and DLP (black bars) following intraprostate injection with rAAV vectors of different serotypes expressing EGFP. EGFP fluorescence intensity of cryo-sections is presented in arbitrary units (a.u.).
  • FIG. 4B shows biodistribution of rAAV genomes in AP (gray bars) and DLP (black bars) following intraprostate injection of rAAV6.2 and rAAV7. Data are presented as rAAV genome copies per diploid genome.
  • FIG. 5 shows intraprostate injection of rAAV vectors and transduction had no adverse effect on prostate histology.
  • FIGs. 6A-6B show rAAV6.2 and 7 could transduce the majority of major prostatic cell types following intraprostate injection.
  • FIG. 6A shows representative images of immunofluorescence staining of prostate luminal cells (top panels), basal cells (middle panels) and stromal cells (bottom panels), marked by K8, K5 and a-actin staining, respectively.
  • FIG. 6B shows quantification of the percentage of EGFP-positive cells of each cell type.
  • FIGs. 7A-7B show data relating to miR34a expression in prostate cancer.
  • FIG. 7A shows qPCR data indicating that miR34a is significantly downregulated in the prostate of TRAMP mice compared to wild type (WT) mice.
  • FIG. 7B shows a luciferase assay demonstrating rAAV-miR34 (pAAVsc- CB PI-miR34a-Gluc) successfully downregulates reporter gene (LacZ/Fluc) expression in vitro.
  • FIGs. 8A-8E show miR34a overexpression inhibits prostate cancer cell cycle.
  • FIG> 8A shows qPCR data demonstrating relative expression level of miR34a in control (mock) and miR34a-treated cells 48 hours post-transfection.
  • FIG. 8B shows a schematic diagram of a prostate cancer cell cycle, highlighting the Gi (2N) and S (2N-4N) phases.
  • FIG. 8C shows transfection with miR34a results in a significant increase in 2N cells compared to mock transfected cells.
  • FIG. 8D shows transfection with miR34a results in a significant decrease in 2N-4N cells compared to mock transfected cells.
  • FIG. 8E shows miR34a overexpression decreases target gene expression (CCND1, TOP2A, and CD44) in vitro.
  • FIGs. 9A-9D show miR34a overexpression reduces cell viability and inhibits migration of PC3 prostate cancer cells.
  • FIG. 9A shows overexpression of miR34a results in a decrease in cell viability of miR34a treated PC3 cells compared to control (Mock) PC3 cells.
  • FIG. 9B shows a significant decrease in OD450 of miR34a-treated PC3 cells compared to control (Mock) PC3 cells.
  • FIG. 9C shows overexpression of miR34a results in reduced PC3 cell migration compared to untreated cells, as measured by a wound healing assay.
  • FIG. 9D shows overexpression of miR34a results in a significant increase in wound width, indicating a reduction in cell migration, compared to control (Mock) cells.
  • FIGs. 10A-10B show miR34a increases the survival rate of TRAMP mice.
  • FIG. 10A shows 2-month old TRAMP mice intraprostatically injected with rAAV7-miR34a (4xlO u GC/mouse) have a significantly lower body weight (e.g., less tumor growth) than PBS-treated control mice.
  • FIG. 10B shows 2-month old TRAMP mice intraprostatically injected with rAAV7-miR34a (4x1 ⁇ 11 GC/mouse) have a significantly improved survival rates (measured by percent survival) compared to PBS-treated control mice.
  • FIG. 11 shows miR34a overexpression ameliorates prostate cancer progression in vivo.
  • 2-month old TRAMP mice were intraprostatically injected with rAAV7-miR34a (4xlO n GC/mouse).
  • miR34a-treated mice show a decrease in prostate tissue pathology in both the anterior prostate (AP) and the dorsal lateral prostate (DLP) compared to PBS- injected control mice.
  • Treatment with miR34a also results in significantly lower neoplasia area compared to control mice.
  • FIGs. 12A-12C show miRNA and target expression in mouse prostate 3 weeks post- intrapro static injection (4xlO n GC/mouse).
  • FIG. 12A shows relative expression of miR34a is significantly increased in miR34a-treated mouse prostate compared to PBS-injected control mice.
  • FIG. 12B shows reporter gene (Glue) expression persists up to 52 weeks post- intrapro static injection of rAAV-miR34a-Gluc.
  • FIG. 12C shows mice treated with miR34a show significant decreases in ALDOA and Sox4 expression compared to PBS-injected control mice 3 weeks post-injection.
  • FIG. 13 shows Western blots demonstrating that miR34a overexpression
  • the disclosure relates in some aspects to compositions and methods for tissue- specific delivery of a transgene by a recombinant adeno-associated virus (rAAV).
  • rAAV recombinant adeno-associated virus
  • the invention relates, in part, to the discovery that rAAV vectors comprising a capsid protein(s) having a certain serotype (e.g., AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.lO) mediate delivery of transgenes to prostate tissue more efficiently than rAAV vectors comprising other capsid protein serotypes.
  • a certain serotype e.g., AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.lO
  • Methods for delivering a transgene to prostate tissue in a subject are provided herein.
  • the methods typically involve administering to a subject an effective amount of a rAAV comprising a nucleic acid for expressing a transgene in the subject.
  • An "effective amount" of a rAAV is an amount sufficient to infect a sufficient number of cells of a target tissue in a subject.
  • a target tissue is prostate tissue.
  • An effective amount of a rAAV may be an amount sufficient to have a therapeutic benefit in a subject, e.g. , to extend the lifespan of a subject, to improve in the subject one or more symptoms of disease, e.g. , a symptom of prostate disease (e.g.
  • an effective amount of a rAAV may be an amount sufficient to produce a stable somatic transgenic animal model.
  • the effective amount will depend on a variety of factors such as, for example, the species, age, weight, health of the subject, and the prostate tissue to be targeted, and may thus vary among subject and tissue.
  • an effective amount may also depend on the rAAV used.
  • the invention is based, in part on the recognition that rAAV comprising capsid proteins having a particular serotype (e.g., AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO) mediate more efficient transduction of prostate tissue that rAAV comprising capsid proteins having a different serotype.
  • the rAAV comprises a capsid protein of an AAV serotype selected from the group consisting of: AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO (SEQ ID NO: 1 to 6).
  • the rAAV comprises a capsid protein of AAV6.2 serotype (SEQ ID NO: 3) or AAV7 serotype (SEQ ID NO: 4).
  • the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1- 7.
  • the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
  • the effective amount of rAAV is 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 genome copies per kg. In certain embodiments, the effective amount of rAAV is 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , or 10 15 genome copies per subject.
  • An effective amount may also depend on the mode of administration. For example, targeting a prostate tissue by intravenous administration or intraperitoneal injection may require different (e.g. , higher) doses, in some cases, than targeting prostate tissue by intraprostate injection.
  • the invention is based, in part, on the recognition that intraperitoneal injection (i.p.) of rAAV does note mediate efficient transduction of prostate cells. Thus, in some embodiments, the injection is not intraperitoneal injection (i.p.).
  • the injection is intraprostate injection. Intraprostate injection can be transperineal, transrectal, or transurethral, as described, for example, in Saemi et al., Indian J Urol.
  • the anatomy of the prostate can be classified in two ways: lobes and zones.
  • the prostate gland has four distinct glandular regions under the zone classification: the peripheral zone (PZ), central zone (CZ), transition zone (TZ), and stroma.
  • the human prostate comprises four lobes: anterior lobe, posterior lobe, lateral lobe, and median lobe.
  • anatomical positions e.g. , an anterior prostate, a dorsal lateral prostate, etc.
  • prostate tissue comprises at least three cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
  • administration of an rAAV as described herein results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells.
  • the prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells.
  • administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
  • Prostate tissue can be healthy prostate tissue (e.g. , prostate tissue not having a disease, or at risk of developing a prostate disease) or diseased prostate tissue (e.g. , prostate tissue having prostatitis, BPH, or prostate cancer).
  • at risk of developing a prostate disease refers to a subject having an increased probability of developing a prostate disease than the general population due to the presence of a risk factor. Examples categories of risk factors for developing prostate disease include, but are not limited to: exposure to
  • carcinogens e.g. , Agent Orange
  • kallikrein levels e.g. , PSA levels
  • age e.g. , race
  • family history e.g. , positive family history of prostate cancer
  • vasectomy e.g. , vasectomy, and dietary fat intake, for example as described in Pienta et al. Ann Intern Med. 118(10):793-803, 1993 and Carter et al. JAMA. 267(16):2215-2220, 1992.
  • the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
  • prostate disease is a disease or condition of the prostate.
  • Non- limiting examples of prostate diseases include, but are not limited to, prostatitis (e.g., acute prostatitis, chronic prostatitis), benign prostate hyperplasia (BPH), prostate cancer (e.g., acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (urothelial cancer), squamous cell prostate cancer, carcinoid tumor of the prostate, small cell prostate cancer, prostate sarcoma (leiomyosarcoma), etc.).
  • prostatitis e.g., acute prostatitis, chronic prostatitis
  • prostate cancer e.g., acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (urothelial cancer), squamous cell prostate cancer, carcinoid tumor of the prostate, small cell prostate cancer, prostate sarcom
  • rAAV -based delivery of a transgene encoding a gene associated with a prostate disease is useful for treatment of subjects having prostate disease.
  • gene associated with a prostate disease refers to any gene, wherein expression of that gene that provides a therapeutic benefit in a subject, e.g., to improve in the subject one or more symptoms of disease, e.g., a symptom of prostate disease (e.g., prostatitis, BPH, prostate cancer, etc.).
  • a gene associated with prostate disease can be a protein, polypeptide, antibody or fragment thereof (e.g., ScFv), toxin, or interfering RNA.
  • genes associated with prostate disease include, but are not limited to Bcl-2, protein kinase C, clusterin, miR34a, miR375, NKX3.1, PTEN, Maspin, CLCA2, and PMSA.
  • Other examples of genes associated with prostate disease are known in the art and are described, for example, in Cooper et al., Nat Clin Pract Urol. Dec;4(12):677- 87; 2007.
  • a gene associated with prostate disease is a microRNA, for example miR34a.
  • miR34a comprises a nucleic acid sequence as set forth in SEQ ID NO: 15.
  • rAAVs Recombinant Adeno-associated Viruses
  • the disclosure provides isolated AAVs.
  • isolated refers to an AAV that has been artificially produced or obtained. Isolated AAVs may be produced using recombinant methods. Such AAVs are referred to herein as "recombinant AAVs".
  • Recombinant AAVs preferably have tissue-specific targeting capabilities, such that a nuclease and/or transgene of the rAAV will be delivered specifically to one or more predetermined tissue(s).
  • the AAV capsid is an important element in determining these tissue-specific targeting capabilities. Thus, an rAAV having a capsid appropriate for the tissue being targeted can be selected.
  • the disclosure provides an rAAV having a capsid appropriate for targeting prostate tissue.
  • the capsid has a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO.
  • the capsid has an AAV6.2 serotype (e.g. , SEQ ID NO: 3) or an AAV7 serotype (e.g. , SEQ ID NO: 4).
  • rAAV described herein may comprise variants of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO serotype capsid proteins.
  • the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7.
  • the methods involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein; a functional rep gene; a recombinant AAV vector composed of, AAV inverted terminal repeats (ITRs) and a transgene; and sufficient helper functions to permit packaging of the
  • capsid proteins are structural proteins encoded by the cap gene of an AAV.
  • AAVs comprise three capsid proteins, virion proteins 1 to 3 (named VP1, VP2 and VP3), all of which are transcribed from a single cap gene via alternative splicing.
  • the molecular weights of VP1, VP2 and VP3 are respectively about 87 kDa, about 72 kDa and about 62 kDa.
  • capsid proteins upon translation, form a spherical 60- mer protein shell around the viral genome.
  • the functions of the capsid proteins are to protect the viral genome, deliver the genome and interact with the host.
  • capsid proteins deliver the viral genome to a host in a tissue specific manner.
  • the components to be cultured in the host cell to package a rAAV vector in an AAV capsid may be provided to the host cell in trans.
  • any one or more of the required components e.g. , recombinant AAV vector, rep sequences, cap sequences, and/or helper functions
  • a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art.
  • a stable host cell will contain the required component(s) under the control of an inducible promoter.
  • the required component(s) may be under the control of a constitutive promoter.
  • a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters.
  • a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contain the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
  • the instant disclosure relates to a host cell containing a nucleic acid that comprises a coding sequence encoding a gene associated with a prostate disease. In some embodiments, the instant disclosure relates to a composition comprising the host cell described above. In some embodiments, the composition comprising the host cell above further comprises a cryopreservative.
  • the recombinant AAV vector, rep sequences, cap sequences, and helper functions required for producing the rAAV of the disclosure may be delivered to the packaging host cell using any appropriate genetic element (vector).
  • the selected genetic element may be delivered by any suitable method, including those described herein.
  • the methods used to construct any embodiment of this disclosure are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g. , Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present disclosure. See, e.g. , K. Fisher et al, J. Virol., 70:520-532 (1993) and U.S. Pat. No. 5,478,745.
  • recombinant AAVs may be produced using the triple transfection method (described in detail in U.S. Pat. No. 6,001,650).
  • the recombinant AAVs are produced by transfecting a host cell with an recombinant AAV vector (comprising a transgene) to be packaged into AAV particles, an AAV helper function vector, and an accessory function vector.
  • An AAV helper function vector encodes the "AAV helper function" sequences (i.e. , rep and cap), which function in trans for productive AAV replication and encapsidation.
  • the AAV helper function vector supports efficient AAV vector production without generating any detectable wild-type AAV virions (i.e.
  • AAV virions containing functional rep and cap genes include pHLP19, described in U.S. Pat. No. 6,001,650 and pRep6cap6 vector, described in U.S. Pat. No. 6,156,303, the entirety of both incorporated by reference herein.
  • the accessory function vector encodes nucleotide sequences for non-AAV derived viral and/or cellular functions upon which AAV is dependent for replication (i.e., "accessory functions").
  • the accessory functions include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid assembly.
  • Viral-based accessory functions can be derived from any of the known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type-1), and vaccinia virus.
  • the disclosure provides transfected host cells.
  • transfection is used to refer to the uptake of foreign DNA by a cell, and a cell has been "transfected” when exogenous DNA has been introduced inside the cell membrane.
  • transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13: 197.
  • Such techniques can be used to introduce one or more exogenous nucleic acids, such as a nucleotide integration vector and other nucleic acid molecules, into suitable host cells.
  • a “host cell” refers to any cell that harbors, or is capable of harboring, a substance of interest. Often a host cell is a mammalian cell. A host cell may be used as a recipient of an AAV helper construct, an AAV minigene plasmid, an accessory function vector, or other transfer DNA associated with the production of recombinant AAVs. The term includes the progeny of the original cell which has been transfected. Thus, a "host cell” as used herein may refer to a cell which has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
  • cell line refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants.
  • the terms "recombinant cell” refers to a cell into which an exogenous DNA segment, such as DNA segment that leads to the transcription of a biologically-active polypeptide or production of a biologically active nucleic acid such as an RNA, has been introduced.
  • vector includes any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells.
  • the term includes cloning and expression vehicles, as well as viral vectors.
  • useful vectors are contemplated to be those vectors in which the nucleic acid segment to be transcribed is positioned under the transcriptional control of a promoter.
  • a “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene.
  • expression vector or construct means any type of genetic construct containing a nucleic acid in which part or all of the nucleic acid encoding sequence is capable of being transcribed.
  • expression includes transcription of the nucleic acid, for example, to generate a biologically-active polypeptide product or functional RNA (e.g., guide RNA) from a transcribed gene.
  • nucleic acid sequence refers to a DNA or RNA sequence.
  • proteins and nucleic acids of the disclosure are isolated.
  • isolated means artificially produced.
  • isolated means: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis.
  • PCR polymerase chain reaction
  • recombinantly produced by cloning recombinantly produced by cloning
  • purified as by cleavage and gel separation
  • iv synthesized by, for example, chemical synthesis.
  • An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art.
  • nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not.
  • An isolated nucleic acid may be substantially purified, but need not be.
  • a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art.
  • isolated refers to a protein or peptide that has been isolated from its natural environment or artificially produced (e.g., by chemical synthesis, by recombinant DNA technology, etc.).
  • conservative amino acid substitutions may be made to provide functionally equivalent variants, or homologs of the capsid proteins.
  • the disclosure embraces sequence alterations that result in conservative amino acid substitutions.
  • a conservative amino acid substitution refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made.
  • Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references that compile such methods, e.g., Molecular Cloning: A Laboratory Manual, J.
  • Conservative substitutions of amino acids include substitutions made among amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Therefore, one can make conservative amino acid substitutions to the amino acid sequence of the proteins and polypeptides disclosed herein.
  • Recombinant AAV (rAAV) vectors are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). It is this recombinant AAV vector which is packaged into a capsid protein and delivered to a selected target cell.
  • the transgene is a nucleic acid sequence, heterologous to the vector sequences, which encodes a polypeptide, protein, functional RNA molecule (e.g. , gRNA) or other gene product, of interest.
  • the nucleic acid coding sequence is operatively linked to regulatory components in a manner which permits transgene transcription, translation, and/or expression in a cell of a target tissue.
  • the instant disclosure relates to a recombinant AAV (rAAV) vector comprising a nucleic acid sequence including a promoter operably linked to a transgene, wherein the transgene is a gene associated with a prostate disease.
  • a rAAV vector further comprises nucleic acid sequences encoding one or more AAV inverted terminal repeat sequences (ITRs), for example AAV2 ITRs.
  • a rAAV vector further comprises nucleic acid sequences encoding one or more AAV ITRs selected from the group consisting of AAV3, AAV4, AAV5, and AAV6.
  • the AAV sequences of the vector typically comprise the cis-acting 5' and 3' inverted terminal repeat sequences (See, e.g. , B. J. Carter, in “Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp. 155 168 (1990)).
  • the ITR sequences are about 145 bp in length.
  • substantially the entire sequences encoding the ITRs are used in the molecule, although some degree of minor modification of these sequences is permissible. The ability to modify these ITR sequences is within the skill of the art. (See, e.g. , texts such as Sambrook et al, "Molecular Cloning.
  • AAV ITR sequences may be obtained from any known AAV, including presently identified mammalian AAV types (e.g. , AAV2, AAV3, AAV4, AAV5, or AAV6 ITR sequences).
  • the vector also includes control elements necessary which are operably linked to the transgene in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector or infected with the virus produced by the disclosure.
  • operably linked sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
  • Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e. , Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
  • polyA polyadenylation
  • a great number of expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.
  • nucleic acid sequence e.g. , coding sequence
  • regulatory sequences are said to be "operably” linked when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequences.
  • nucleic acid sequences be translated into a functional protein
  • two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame- shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein.
  • a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.
  • operably linked coding sequences yield a fusion protein.
  • operably linked coding sequences yield a functional RNA (e.g. , gRNA).
  • a polyadenylation sequence generally is inserted following the transgene sequences and before the 3' AAV ITR sequence.
  • a rAAV construct useful in the present disclosure may also contain an intron, desirably located between the promoter/enhancer sequence and the transgene.
  • One possible intron sequence is derived from SV-40, and is referred to as the SV-40 T intron sequence.
  • Another vector element that may be used is an internal ribosome entry site (IRES).
  • An IRES sequence is used to produce more than one polypeptide from a single gene transcript.
  • An IRES sequence would be used to produce a protein that contain more than one polypeptide chains.
  • a Foot and Mouth Disease Virus 2A sequence is included in polyprotein; this is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of polyproteins (Ryan, M D et al., EMBO, 1994; 4: 928-933; Mattion, N M et al., J Virology, November 1996; p. 8124-8127; Furler, S et al., Gene Therapy, 2001 ; 8: 864-873; and Halpin, C et al., The Plant Journal, 1999; 4: 453-459).
  • the cleavage activity of the 2A sequence has previously been
  • regulatory sequences needed for gene expression in host cells may vary between species, tissues or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, enhancer elements, and the like.
  • 5' non-transcribed regulatory sequences will include a promoter region that includes a promoter sequence for
  • Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired.
  • the vectors of the disclosure may optionally include 5' leader or signal sequences.
  • constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the
  • CMV cytomegalovirus
  • PGK phosphoglycerol kinase
  • a promoter is an enhanced chicken ⁇ -actin promoter.
  • Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g. , acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art.
  • inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex) -inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088); the ecdysone insect promoter (No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (1996)), the tetracycline-repressible system (Gossen et al, Proc. Natl. Acad. Sci.
  • MT zinc-inducible sheep metallothionine
  • Dex dexamethasone
  • MMTV mouse mammary tumor virus
  • T7 polymerase promoter system WO 98/10088
  • ecdysone insect promoter No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (1996)
  • inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g. , temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
  • the native promoter for the transgene will be used.
  • the native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression.
  • the native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue- specific manner, or in response to specific transcriptional stimuli.
  • other native expression control elements such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.
  • the regulatory sequences impart tissue-specific gene expression capabilities.
  • the tissue-specific regulatory sequences bind tissue-specific transcription factors that induce transcription in a tissue specific manner.
  • tissue-specific regulatory sequences e.g. , promoters, enhancers, etc..
  • tissue-specific regulatory sequences are well known in the art.
  • tissue-specific regulatory sequences include, but are not limited to the following tissue specific promoters: a liver- specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin promoter, a pancreatic polypeptide (PPY) promoter, a synapsin-1 (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a a-myosin heavy chain (a-MHC) promoter, or a cardiac Troponin T (cTnT) promoter.
  • TSG liver- specific thyroxin binding globulin
  • PY pancreatic polypeptide
  • PPY pancreatic polypeptide
  • Syn synapsin-1
  • MCK creatine kinase
  • DES mammalian desmin
  • a-MHC a-myosin heavy chain
  • Beta-actin promoter hepatitis B virus core promoter, Sandig et al., Gene Ther., 3: 1002-9 (1996); alpha-fetoprotein (AFP) promoter, Arbuthnot et al., Hum. Gene Ther., 7: 1503-14 (1996)), bone osteocalcin promoter (Stein et al., Mol. Biol. Rep., 24: 185-96 (1997)); bone sialoprotein promoter (Chen et al., J. Bone Miner. Res., 11:654-64 (1996)), CD2 promoter (Hansal et al., J.
  • AFP alpha-fetoprotein
  • Immunol., 161: 1063-8 (1998); immunoglobulin heavy chain promoter; T cell receptor a-chain promoter, neuronal such as neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., 13:503-15 (1993)), neurofilament light-chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron- specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)), among others which will be apparent to the skilled artisan.
  • NSE neuron-specific enolase
  • the promoter is a prostate-specific promoter, for example a prostate-specific antigen (PSA) promoter, a probasin promoter, a Moloney murine leukemia virus long terminal repeat (MMTV LTR) promoter, etc.
  • PSA prostate-specific antigen
  • MMTV LTR Moloney murine leukemia virus long terminal repeat
  • one or more bindings sites for one or more of miRNAs are incorporated in a transgene of a rAAV vector, to inhibit the expression of the transgene in one or more tissues of an subject harboring the transgene.
  • binding sites may be selected to control the expression of a transgene in a tissue specific manner.
  • binding sites for the liver- specific miR-122 may be incorporated into a transgene to inhibit expression of that transgene in the liver.
  • the target sites in the mRNA may be in the 5' UTR, the 3' UTR or in the coding region. Typically, the target site is in the 3' UTR of the mRNA.
  • the transgene may be designed such that multiple miRNAs regulate the mRNA by recognizing the same or multiple sites.
  • the presence of multiple miRNA binding sites may result in the cooperative action of multiple RISCs and provide highly efficient inhibition of expression.
  • the target site sequence may comprise a total of 5-100, 10-60, or more nucleotides.
  • the target site sequence may comprise at least 5 nucleotides of the sequence of a target gene binding site.
  • miRNAs In some aspects, the disclosure relates to delivery of a transgene encoding microRNA 34a (miR34a) to a cell. miRNAs are natively expressed, typically as final 19-25 non- translated RNA products.
  • miRNAs exhibit their activity through sequence- specific interactions with the 3' untranslated regions (UTR) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors which are subsequently processed into a miRNA duplex, and further into a "mature" single stranded miRNA molecule. This mature miRNA guides a multiprotein complex, miRISC, which identifies target site, e.g. , in the 3' UTR regions, of target mRNAs based upon their complementarity to the mature miRNA.
  • miRISC multiprotein complex
  • miR34a is known to function as a regulator of tumor suppression in cells. Accordingly, in some embodiments, delivery of a transgene encoding miR34a to a cell is useful for treatment of certain diseases characterized by reduction of miR34a expression or activity (e.g. , certain cancers). Examples of cancers characterized by a reduction of miR34a expression or activity include but are not limited to prostate cancer, pancreatic cancer, breast cancer, colorectal cancer, cervical cancer, certain brain cancers (e.g. , glioblastoma, medulloblastoma, etc.). In some embodiments, miR34a regulates cancer stem cells, such as prostate cancer stem cells, lung cancer stem cells, etc. , for example as described in Misso et al. (2014) Mol. Ther. Nucleic Acids 3, el94;
  • the disclosure provides a method for treating cancer, the method comprising delivering a transgene encoding miR34a to a subject having a cancer characterized by a reduction in mir34a expression or activity.
  • the disclosure relates to the discovery that overexpression of certain miRNAs (e.g. , miR34a) reduces prostate cancer cell viability and cell migration.
  • miRNAs e.g. , miR34a
  • the disclosure provides methods and compositions for treating prostate cancer by overexpressing miRNAs (e.g. , miR34a) in a subject in need thereof.
  • miRNAs e.g. , miR34a
  • miRNAs and other small interfering nucleic acids regulate gene expression via target RNA transcript cleavage/degradation or translational repression of the target messenger RNA (mRNA).
  • mRNA target messenger RNA
  • a miR34a miRNA described by the disclosure comprises or consists of a nucleic acid sequence as set forth in SEQ ID NO: 15. Variants of SEQ ID NO: 15 are also contemplated by the disclosure. For example, in some embodiments, a miR34a sequence is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 15.
  • a miR34a miRNA is an inhibitory nucleic acid (e.g., miRNA, pri-miRNA, amiRNA, dsRNA, shRNA, siRNA, etc.) that is complementary with and specifically binds to a target site sequence (e.g., a miR34a binding site) of a gene (e.g., CCND1, TOP2A, CD44, etc.) and inhibits expression of the target sequence (e.g., inhibits transcription, translation, or production a protein encoded by the target sequence).
  • a target sequence comprises at least 5 contiguous nucleotides that are complementary with a sequence as set forth in SEQ ID NO: 15.
  • the rAAVs may be delivered to a subject in compositions according to any appropriate methods known in the art.
  • the rAAV preferably suspended in a physiologically compatible carrier (i.e., in a composition) may be administered to a subject, i.e. host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate (e.g., Macaque).
  • a host animal does not include a human.
  • Delivery of the rAAVs to a mammalian subject may be by, for example, intraprostate injection.
  • the intraprostate injection is transperineal, transrectal, or transurethral injection.
  • the injection is not intraperitoneal injection
  • compositions of the disclosure may comprise an rAAV alone, or in combination with one or more other viruses (e.g., a second rAAV encoding having one or more different transgenes).
  • a composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different rAAVs each having one or more different transgenes.
  • a composition further comprises a pharmaceutically acceptable carrier.
  • suitable carriers may be readily selected by one of skill in the art in view of the indication for which the rAAV is directed.
  • one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline).
  • Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present disclosure.
  • compositions of the disclosure may contain, in addition to the rAAV and carrier(s), other pharmaceutical ingredients, such as preservatives, or chemical stabilizers.
  • suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.
  • Suitable chemical stabilizers include gelatin and albumin.
  • the rAAVs are administered in sufficient amounts to transfect the cells of a desired tissue (e.g. , prostate tissue) and to provide sufficient levels of gene transfer and expression without undue adverse effects.
  • a desired tissue e.g. , prostate tissue
  • routes of administration include, but are not limited to, direct delivery to the selected organ (e.g. , intraprostate delivery to the prostate), oral, inhalation (including intranasal and intratracheal delivery), intraocular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parental routes of administration. Routes of administration may be combined, if desired.
  • the dose of rAAV virions required to achieve a particular "therapeutic effect,” e.g. , the units of dose in genome copies/per kilogram of body weight (GC/kg), will vary based on several factors including, but not limited to: the route of rAAV virion administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product.
  • a rAAV virion dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors.
  • an effective amount of an rAAV is an amount sufficient to target infect an animal, target a desired tissue.
  • an effective amount of an rAAV is an amount sufficient to produce a stable somatic transgenic animal model.
  • the effective amount will depend primarily on factors such as the species, age, weight, health of the subject, and the tissue to be targeted, and may thus vary among animal and tissue.
  • an effective amount of the rAAV is generally in the range of from about 1 ml to about 100 ml of solution containing from about 10 9 to 10 16 genome copies. In some cases, a dosage between about
  • a dose of rAAV is administered to a subject no more than once per calendar day (e.g. , a 24-hour period).
  • a dose of rAAV is administered to a subject no more than once per 2, 3, 4, 5, 6, or 7 calendar days.
  • a dose of rAAV is administered to a subject no more than once per calendar week (e.g. , 7 calendar days).
  • a dose of rAAV is administered to a subject no more than bi-weekly (e.g. , once in a two calendar week period). In some embodiments, a dose of rAAV is administered to a subject no more than once per calendar month (e.g. , once in 30 calendar days). In some embodiments, a dose of rAAV is
  • a dose of rAAV is administered to a subject no more than once per calendar year (e.g. , 365 days or 366 days in a leap year).
  • rAAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high rAAV concentrations are present
  • Formulation of pharmaceutically-acceptable excipients and carrier solutions is well- known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.
  • these formulations may contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation.
  • the amount of active compound in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.
  • Factors such as solubility,
  • rAAVs in suitably formulated pharmaceutical compositions disclosed herein are delivered directly to target tissue, e.g., direct to prostate tissue.
  • target tissue e.g., direct to prostate tissue.
  • intraopancreatically intranasally, parenterally, intravenously, intramuscularly, intrathecally, or orally, intraperitoneally, or by inhalation.
  • the administration modalities as described in U.S. Pat. Nos. 5,543,158; 5,641,515 and 5,399,363 may be used to deliver rAAVs.
  • a preferred mode of administration is by intraprostate injection.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In many cases the form is sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. , glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
  • polyol e.g. , glycerol, propylene glycol, and liquid polyethylene glycol, and the like
  • suitable mixtures thereof e.g. , glycerol, propylene glycol, and liquid polyethylene glycol, and the like
  • vegetable oils e.g. , glycerol, propylene glycol, and liquid polyethylene glycol, and the like
  • Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, paraben
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • a suitable sterile aqueous medium may be employed.
  • one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the appropriate dose for the individual host.
  • Sterile injectable solutions are prepared by incorporating the active rAAV in the required amount in the appropriate solvent with various of the other ingredients enumerated herein, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the rAAV compositions disclosed herein may also be formulated in a neutral or salt form.
  • Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
  • carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • solvents dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • Supplementary active ingredients can also be incorporated into the compositions.
  • pharmaceutically-acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a host.
  • Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present disclosure into suitable host cells.
  • the rAAV vector delivered trangenes may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.
  • Such formulations may be preferred for the introduction of pharmaceutically acceptable formulations of the nucleic acids or the rAAV constructs disclosed herein.
  • the formation and use of liposomes is generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
  • Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed.
  • Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs).
  • MLVs generally have diameters of from 25 nm to 4 ⁇ . Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 .ANG., containing an aqueous solution in the core.
  • SUVs small unilamellar vesicles
  • Nanocapsule formulations of the rAAV may be used.
  • Nanocapsules can generally entrap substances in a stable and reproducible way.
  • ultrafine particles sized around 0.1 ⁇
  • Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use.
  • kits may include one or more containers housing the components of the disclosure and instructions for use.
  • kits may include one or more agents described herein, along with instructions describing the intended application and the proper use of these agents.
  • agents in a kit may be in a
  • Kits for research purposes may contain the components in appropriate concentrations or quantities for running various experiments.
  • the instant disclosure relates to a kit for producing a rAAV, the kit comprising a container housing an isolated nucleic acid encoding an AAV capsid protein selected from any one of SEQ ID NO: 1-7.
  • the kit further comprises instructions for producing the rAAV.
  • the kit further comprises at least one container housing a recombinant AAV vector, wherein the recombinant AAV vector comprises a transgene (e.g. , a gene associated with prostate disease).
  • the instant disclosure relates to a kit comprising a container housing a recombinant AAV having an isolated AAV capsid protein having an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
  • the kit may be designed to facilitate use of the methods described herein by researchers and can take many forms.
  • Each of the compositions of the kit may be provided in liquid form (e.g. , in solution), or in solid form, (e.g. , a dry powder).
  • some of the compositions may be constitutable or otherwise processable (e.g. , to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit.
  • a suitable solvent or other species for example, water or a cell culture medium
  • Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g. , videotape, DVD, etc.), Internet, and/or web-based
  • the written instructions may be in a form prescribed by a
  • the kit may contain any one or more of the components described herein in one or more containers.
  • the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject.
  • the kit may include a container housing agents described herein.
  • the agents may be in the form of a liquid, gel or solid (powder).
  • the agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other container for storage. A second container may have other agents prepared sterilely.
  • the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container.
  • the kit may have one or more or all of the components required to administer the agents to an animal, such as a syringe, topical application devices, or iv needle tubing and bag, particularly in the case of the kits for producing specific somatic animal models.
  • the kit may have a variety of forms, such as a blister pouch, a shrink wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box or a bag.
  • the kit may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped.
  • the kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art.
  • the kit may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
  • other components for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
  • kits of the disclosure may involve methods for detecting a latent AAV in a cell.
  • kits of the disclosure may include, instructions, a negative and/or positive control, containers, diluents and buffers for the sample, sample preparation tubes and a printed or electronic table of reference AAV sequence for sequence comparisons.
  • AAV5 capsid protein nucleic acid sequence (SEQ ID NO: 8)
  • AAV6 capsid nucleic acid sequence (SEQ ID NO: 9)
  • Example 1 Adeno-associated virus serotype vectors efficiently transduce normal prostate tissue and prostate cancer cells
  • EGFP enhanced green fluorescent protein
  • EGFP fluorescence signal was barely observed in the prostate tissue sections three weeks after vector injection, indicating inefficient transduction.
  • the same panel of rAAV vectors was injected directly into mouse prostate.
  • the mouse prostate is divided into anterior prostate (AP) that contains two lobes and dorsal lateral prostate (DLP) (FIG. 1).
  • rAAV vectors were thus injected into four sites per prostate, namely the two lobes of AP and two sites of DLP (FIG. 1).
  • rAAV6.2, rAAV7 and rAAV9 outperformed the other serotypes in transducing AP (FIGs. 2A-2B, FIG. 4A).
  • rAAV6.2 and rAAV7 also transduced DLP efficiently (FIGs. 3A-3B, FIG. 4A).
  • rAAV5, rAAV8 and rAAVrh.10 transduced DLP (FIG. 3A, FIG. 4A).
  • PCa Prostate cancer
  • miR-34a is significantly downregulated in PCa cells.
  • downregulation of miR34a in prostate tumor from transgenic adenocarcinoma mouse prostate (TRAMP) model was examined.
  • Relative expression of miR34a in prostate tissue of wild type and TRAMP mice was quantified by quantitative PCR (qPCR).
  • Results demonstrate that expression of miR34a is significantly downregulated in the TRAMP mice (FIG. 7A).
  • An rAAV-pri-miR34a construct was produced and tested using a luciferase assay. Results indicate that the rAAV-pir-miR34a construct efficiently downregulates expression of the reporter gene ⁇ e.g., luciferase) (FIG. 7B) in vitro.
  • miR34a overexpression inhibits growth of prostate cancer cells (FIG. 8A).
  • overexpression of miR-34a significantly inhibits the cell cycle of PC3 cells (FIG. 8B) by prolonging Gi (FIG. 8C-8D)and shortening S phases through targeting cyclin Dl (CCND1), CD44, and DNA topoisomerase 2-alpha (TOP 2 A), as shown in FIG. 8E.
  • miR34a overexpression reduces cell viability (FIGs. 9A-9B) and inhibits cell migration of PC3 cells as measured by a wound healing assay (FIG. 9C-9D).
  • rAAV7-miR34a Treatment with rAAV7-miR34a lowered body weights significantly (p ⁇ 0.05) as compared to the control group starting from 24 weeks after injection, likely a result of the higher tumor burden in the control group (FIG. 10A). rAAV7-miR34a treatment also significantly extended the lifespan of TRAMP mice (p ⁇ 0.05) (FIG. 10B). Moreover, proliferation and neoplasia in the rAAV7-mir34a treated prostates were significantly diminished in both the anterior prostate (AP) and dorsal lateral prostate (DLP) when compared to those in the control group (FIG. 11).
  • AP anterior prostate
  • DLP dorsal lateral prostate
  • miRNA and reporter expression in mouse prostate were measured by qPCR and reporter (Glue) assay 3 weeks post intrapro static injection. Results indicate that miR34 expression is highly upregulated in treated mice versus control mice (FIG. 12A) and that miR34 expression persists for up to 52 weeks after injection (FIG. 12B). It was also observed that expression of Aldolase A, Fructose-Bisphosphate (ALDOA) and Sex Determining Region Y)-Box 4 (Sox4) were significantly downregulated in miR34a-treated mouse prostate compared to untreated control mouse prostate (FIG. 12C). Relative protein expression results were confirmed by Western blot, which show miR34a overexpression downregulates ALDOA, Ccndl, and Sox4 expression in mouse prostate (FIG. 13).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The disclosure relates to compositions and methods for rAAV-mediated delivery of a transgene to a subject. In some embodiments, the rAAV transduces the prostate tissue of a subject. In some embodiments, the methods are useful for treatment of prostate disease (e.g., prostatitis, BPH, prostate cancer).

Description

PROSTATE-TARGETING ADENO-ASSOCIATED VIRUS SEROTYPE VECTORS
RELATED APPLICATIONS
This Application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application Serial No. 62/245,027, filed October 22, 2015, and U.S. Provisional Application Serial No. 62/322,285, filed April 14, 2016, the entire contents of each of which are incorporated by reference herein.
BACKGROUND
The prostate is an exocrine gland that is crucial to constituting the male reproductive system, and the functions of prostate are similar in the majority of mammals despite anatomical differences. Three types of prostate diseases are the major threats for the health of prostate, i.e., prostatitis, benign prostate hyperplasia (BPH) and prostate cancer. Together, these prostate diseases are severely compromising the life quality and life span of males, especially for the aged male population. For example, BPH is one of the top ten most costly diseases among male populations over 50-year old in the USA, and prostate cancer is the second most diagnosed malignancy and the sixth leading cause for mortality of all cancers in males worldwide.
To date, many efforts have been made to prevent or to treat prostate diseases, including surgery, medication, and radiotherapy. Nevertheless, highly effective clinical interventions for a variety of prostate diseases are still lacking. For example, although the early stage of prostate cancer can be prevented with hormonal therapy, most hormone- dependent prostate cancers will eventually develop into castration-resistant prostate cancer (CRPC). So far, no effective treatment exists for CRPC. As the genetic basis of prostate diseases was gradually unraveled during the past decades, gene therapy was explored as a therapeutic strategy for prostate diseases, and researchers have demonstrated the feasibility of several gene therapy approaches to treating BPH and prostate cancer in mice using various types of viral gene delivery vectors. However, many viral vectors, such as adenovirus, lentivirus and retrovirus, can cause insertional genotoxicity and/or immunotoxicity, which greatly limits their clinical use. SUMMARY
Adeno-associated virus (AAV) is a single-stranded DNA virus, and recombinant AAV (rAAV) vectors possess many advantages in gene therapy applications, including low immunogenicity and genotoxicity, broad tissue tropism and high transduction efficiency in vivo, and long-term transgene expression. Aspects of the invention are related to the discovery that rAAV vectors comprising capsid proteins having a certain serotype, including, but not limited to, AAV5, AAV6.2, AAV7, AAV8, AAV9, AAVrh. lO, mediate delivery of transgenes to prostate tissue more efficiently than other vectors (e.g. , rAAV vectors comprising other capsid protein serotypes).
Accordingly in some aspects, the disclosure provides a method for delivering a transgene to prostate tissue, the method comprising: administering to prostate tissue of a subject an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
In some aspects, the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.10, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
In some embodiments, the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7. In some embodiments, the capsid protein comprises an amino acid sequence as set forth in SEQ ID NO: 3 or 4. In some embodiments, the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
In some embodiments, the transgene encodes a gene associated with a prostate disease. In some embodiments, the prostate disease is selected from prostatitis, prostate cancer and benign prostate hyperplasia (BPH). In some embodiments, the gene encodes a tumor suppressor molecule (e.g. , a tumor suppressor protein or a miRNA that regulates tumor suppression). In some embodiments, the gene encodes BCL-2, PTEN, SLC39A1, BRCA1, BRCA2, HPCl, RUNX2, CLCA2, YAPl, MASPIN, LL37, CDKNIB, AR, NKX3.1, CASP9, FKHR, GSK3, MDM2, ERK1/2, PSA, CCND1, ALDOA, Sox4, CD44, and miR34a.
In some aspects, the disclosure is based on the discovery that miR34a expression is downregulated in prostate cancer cells. In some embodiments, overexpression of miR34a in prostate cancer cells results in decreased cancer cell viability and migration. Accordingly, in some aspects, the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of a nucleic acid comprising a promoter operably linked to a transgene, wherein the transgene encodes miR34a. In some embodiments, the transgene comprises or consists of a nucleic acid having a sequence as set forth in SEQ ID NO: 15. In some embodiments, the nucleic acid comprises or consists of a nucleic acid having a sequence as set forth in SEQ ID NO: 16.
In some embodiments, the administration occurs by injection. In some embodiments, the injection is not intraperitoneal injection (i.p.). In some embodiments, the injection is intrapro state injection.
In some embodiments, the administration results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells. In some embodiments, the administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
In some embodiments, the rAAV further comprises two AAV inverted terminal repeats (ITRs), wherein the ITRs flank the transgene. In some embodiments, the AAV ITRs are ITRs of one or more serotypes selected from: AAV2, AAV3, AAV4, AAV5, and AAV6.
In some embodiments, the subject is a mammal, optionally a human.
Each of the limitations of the disclosure can encompass various embodiments of the disclosure. It is, therefore, anticipated that each of the limitations of the disclosure involving any one element or combinations of elements can be included in each aspect of the
disclosure. This disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows a graphical depiction of the anatomical structure of mouse prostate and intraprostate injection sites. lxlO11 GC per injection site of rAAV vectors were delivered into four sites as indicated by the syringes, namely the two lobes of the anterior prostate (AP) and two sites in the dorsal lateral prostate (DLP). SV: seminal vesicle.
FIGs. 2A-2B show rAAV6.2, 7 and 9 efficiently transduced mouse AP following intraprostate injection. FIG. 2A shows representative fluorescence images of anterior prostate (AP) cryo-sections showing the merge of EGFP native fluorescence and nuclear staining by DAPI following injections of each of 12 rAAV serotypes or PBS. Squared regions indicate the locations of high magnification images shown in (FIG. 2B). Scale bars represent 100 microns. FIG. 2B shows high magnification images of AP cryo-sections following PBS injection or transduction with rAAV6.2 and 7. Scale bars represent 25 microns.
FIGs. 3A-3B show rAAV6.2, and 7 efficiently transduced mouse DLP following intraprostate injection. FIG. 3A shows representative fluorescence images of dorsal lateral prostate (DLP) cryo-sections showing the merge of EGFP native fluorescence and nuclear staining by DAPI following injections of each of 12 rAAV serotypes or PBS. Squared regions indicate the locations of high magnification images shown in (FIG. 3B). Scale bars represent 100 microns. FIG. 3B shows high magnification images of DLP cryo-sections following PBS injection or transduction with rAAV6.2 and 7. Scale bars represent 25 microns.
FIGs. 4A-4B show rAAV6.2 and rAAV7 efficiently transduced mouse prostate following intraprostate injection. FIG. 4A shows quantification of transduction efficiency in AP (gray bars) and DLP (black bars) following intraprostate injection with rAAV vectors of different serotypes expressing EGFP. EGFP fluorescence intensity of cryo-sections is presented in arbitrary units (a.u.). FIG. 4B shows biodistribution of rAAV genomes in AP (gray bars) and DLP (black bars) following intraprostate injection of rAAV6.2 and rAAV7. Data are presented as rAAV genome copies per diploid genome.
FIG. 5 shows intraprostate injection of rAAV vectors and transduction had no adverse effect on prostate histology. Representative H&E staining images of AP and DLP tissue sections collected from mice that were not treated (untreated), treated with PBS, or three rAAV serotype vectors including rAAV6.2, 7 and 9. Scale bars represent 100 microns. FIGs. 6A-6B show rAAV6.2 and 7 could transduce the majority of major prostatic cell types following intraprostate injection. FIG. 6A shows representative images of immunofluorescence staining of prostate luminal cells (top panels), basal cells (middle panels) and stromal cells (bottom panels), marked by K8, K5 and a-actin staining, respectively. Nuclear staining by DAPI, native EGFP fluorescence images and merged images from the same sections are also shown. Arrows indicate representative co- localization of EGFP signal and cell type marker signal. FIG. 6B shows quantification of the percentage of EGFP-positive cells of each cell type.
FIGs. 7A-7B show data relating to miR34a expression in prostate cancer. FIG. 7A shows qPCR data indicating that miR34a is significantly downregulated in the prostate of TRAMP mice compared to wild type (WT) mice. FIG. 7B shows a luciferase assay demonstrating rAAV-miR34 (pAAVsc- CB PI-miR34a-Gluc) successfully downregulates reporter gene (LacZ/Fluc) expression in vitro.
FIGs. 8A-8E show miR34a overexpression inhibits prostate cancer cell cycle. FIG> 8A shows qPCR data demonstrating relative expression level of miR34a in control (mock) and miR34a-treated cells 48 hours post-transfection. FIG. 8B shows a schematic diagram of a prostate cancer cell cycle, highlighting the Gi (2N) and S (2N-4N) phases. FIG. 8C shows transfection with miR34a results in a significant increase in 2N cells compared to mock transfected cells. FIG. 8D shows transfection with miR34a results in a significant decrease in 2N-4N cells compared to mock transfected cells. FIG. 8E shows miR34a overexpression decreases target gene expression (CCND1, TOP2A, and CD44) in vitro.
FIGs. 9A-9D show miR34a overexpression reduces cell viability and inhibits migration of PC3 prostate cancer cells. FIG. 9A shows overexpression of miR34a results in a decrease in cell viability of miR34a treated PC3 cells compared to control (Mock) PC3 cells. FIG. 9B shows a significant decrease in OD450 of miR34a-treated PC3 cells compared to control (Mock) PC3 cells. FIG. 9C shows overexpression of miR34a results in reduced PC3 cell migration compared to untreated cells, as measured by a wound healing assay. FIG. 9D shows overexpression of miR34a results in a significant increase in wound width, indicating a reduction in cell migration, compared to control (Mock) cells.
FIGs. 10A-10B show miR34a increases the survival rate of TRAMP mice. FIG. 10A shows 2-month old TRAMP mice intraprostatically injected with rAAV7-miR34a (4xlOu GC/mouse) have a significantly lower body weight (e.g., less tumor growth) than PBS-treated control mice. FIG. 10B shows 2-month old TRAMP mice intraprostatically injected with rAAV7-miR34a (4x1ο11 GC/mouse) have a significantly improved survival rates (measured by percent survival) compared to PBS-treated control mice.
FIG. 11 shows miR34a overexpression ameliorates prostate cancer progression in vivo. 2-month old TRAMP mice were intraprostatically injected with rAAV7-miR34a (4xlOn GC/mouse). miR34a-treated mice show a decrease in prostate tissue pathology in both the anterior prostate (AP) and the dorsal lateral prostate (DLP) compared to PBS- injected control mice. Treatment with miR34a also results in significantly lower neoplasia area compared to control mice.
FIGs. 12A-12C show miRNA and target expression in mouse prostate 3 weeks post- intrapro static injection (4xlOn GC/mouse). FIG. 12A shows relative expression of miR34a is significantly increased in miR34a-treated mouse prostate compared to PBS-injected control mice. FIG. 12B shows reporter gene (Glue) expression persists up to 52 weeks post- intrapro static injection of rAAV-miR34a-Gluc. FIG. 12C shows mice treated with miR34a show significant decreases in ALDOA and Sox4 expression compared to PBS-injected control mice 3 weeks post-injection.
FIG. 13 shows Western blots demonstrating that miR34a overexpression
downregulates Aldoa, Ccndl, and Sox4 expression in mouse prostate compared to control mouse prostate.
DETAILED DESCRIPTION
The disclosure relates in some aspects to compositions and methods for tissue- specific delivery of a transgene by a recombinant adeno-associated virus (rAAV). The invention relates, in part, to the discovery that rAAV vectors comprising a capsid protein(s) having a certain serotype (e.g., AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.lO) mediate delivery of transgenes to prostate tissue more efficiently than rAAV vectors comprising other capsid protein serotypes.
Methods and Compositions for AAV -mediated Delivery of a Transgene to Prostate Tissue
Methods for delivering a transgene to prostate tissue in a subject are provided herein. The methods typically involve administering to a subject an effective amount of a rAAV comprising a nucleic acid for expressing a transgene in the subject. An "effective amount" of a rAAV is an amount sufficient to infect a sufficient number of cells of a target tissue in a subject. In some embodiments, a target tissue is prostate tissue. An effective amount of a rAAV may be an amount sufficient to have a therapeutic benefit in a subject, e.g. , to extend the lifespan of a subject, to improve in the subject one or more symptoms of disease, e.g. , a symptom of prostate disease (e.g. , prostatitis, BPH, prostate cancer, etc.). In some cases, an effective amount of a rAAV may be an amount sufficient to produce a stable somatic transgenic animal model. The effective amount will depend on a variety of factors such as, for example, the species, age, weight, health of the subject, and the prostate tissue to be targeted, and may thus vary among subject and tissue.
An effective amount may also depend on the rAAV used. The invention is based, in part on the recognition that rAAV comprising capsid proteins having a particular serotype (e.g., AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO) mediate more efficient transduction of prostate tissue that rAAV comprising capsid proteins having a different serotype. Thus in some embodiments, the rAAV comprises a capsid protein of an AAV serotype selected from the group consisting of: AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO (SEQ ID NO: 1 to 6). In some embodiments, the rAAV comprises a capsid protein of AAV6.2 serotype (SEQ ID NO: 3) or AAV7 serotype (SEQ ID NO: 4). In some embodiments, the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1- 7. In some embodiments, the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
In certain embodiments, the effective amount of rAAV is 1010, 1011, 1012, 1013, or 1014 genome copies per kg. In certain embodiments, the effective amount of rAAV is 1010, 1011, 1012, 1013, 1014, or 1015 genome copies per subject.
An effective amount may also depend on the mode of administration. For example, targeting a prostate tissue by intravenous administration or intraperitoneal injection may require different (e.g. , higher) doses, in some cases, than targeting prostate tissue by intraprostate injection. The invention is based, in part, on the recognition that intraperitoneal injection (i.p.) of rAAV does note mediate efficient transduction of prostate cells. Thus, in some embodiments, the injection is not intraperitoneal injection (i.p.). In some embodiments, the injection is intraprostate injection. Intraprostate injection can be transperineal, transrectal, or transurethral, as described, for example, in Saemi et al., Indian J Urol. Jul-Sep; 24(3): 329- 335; 2008. In some cases, multiple doses of a rAAV are administered. Generally, the anatomy of the prostate can be classified in two ways: lobes and zones. For example, in humans the prostate gland has four distinct glandular regions under the zone classification: the peripheral zone (PZ), central zone (CZ), transition zone (TZ), and stroma. Under the lobe classification, the human prostate comprises four lobes: anterior lobe, posterior lobe, lateral lobe, and median lobe. In other species different terminology may be used to refer to different prostate structures, for example, in mouse prostate sites are referred to using anatomical positions, e.g. , an anterior prostate, a dorsal lateral prostate, etc. See, for example, Selth, et al. International Journal of Cancer. 131(3):652-661, 2012, and Wang, et al. Cancer Cell. 4(3):209-221, 2003. No matter the classification system, prostate tissue comprises at least three cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells. In some embodiments, administration of an rAAV as described herein results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells. In some embodiments, the
administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
Prostate tissue can be healthy prostate tissue (e.g. , prostate tissue not having a disease, or at risk of developing a prostate disease) or diseased prostate tissue (e.g. , prostate tissue having prostatitis, BPH, or prostate cancer). As used herein, "at risk of developing a prostate disease" refers to a subject having an increased probability of developing a prostate disease than the general population due to the presence of a risk factor. Examples categories of risk factors for developing prostate disease include, but are not limited to: exposure to
carcinogens (e.g. , Agent Orange), kallikrein levels (e.g. , PSA levels) age, race, family history (e.g. , positive family history of prostate cancer), vasectomy, and dietary fat intake, for example as described in Pienta et al. Ann Intern Med. 118(10):793-803, 1993 and Carter et al. JAMA. 267(16):2215-2220, 1992.
Without wishing to be bound by any particular theory, efficient transduction of luminal, basal, and/or stromal prostate cells by rAAV described herein may be useful for the treatment of a subject having a prostate disease. Accordingly, methods and compositions for treating prostate disease are also provided herein. In some aspects, the disclosure provides a method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
As used herein, a "prostate disease" is a disease or condition of the prostate. Non- limiting examples of prostate diseases include, but are not limited to, prostatitis (e.g., acute prostatitis, chronic prostatitis), benign prostate hyperplasia (BPH), prostate cancer (e.g., acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (urothelial cancer), squamous cell prostate cancer, carcinoid tumor of the prostate, small cell prostate cancer, prostate sarcoma (leiomyosarcoma), etc.).
Without wishing to be bound by any particular theory, rAAV -based delivery of a transgene encoding a gene associated with a prostate disease is useful for treatment of subjects having prostate disease. As used herein, "gene associated with a prostate disease" refers to any gene, wherein expression of that gene that provides a therapeutic benefit in a subject, e.g., to improve in the subject one or more symptoms of disease, e.g., a symptom of prostate disease (e.g., prostatitis, BPH, prostate cancer, etc.). A gene associated with prostate disease can be a protein, polypeptide, antibody or fragment thereof (e.g., ScFv), toxin, or interfering RNA. Examples of genes associated with prostate disease include, but are not limited to Bcl-2, protein kinase C, clusterin, miR34a, miR375, NKX3.1, PTEN, Maspin, CLCA2, and PMSA. Other examples of genes associated with prostate disease are known in the art and are described, for example, in Cooper et al., Nat Clin Pract Urol. Dec;4(12):677- 87; 2007. In some embodiments, a gene associated with prostate disease is a microRNA, for example miR34a. In some embodiments, miR34a comprises a nucleic acid sequence as set forth in SEQ ID NO: 15.
Recombinant Adeno-associated Viruses (rAAVs)
In some aspects, the disclosure provides isolated AAVs. As used herein with respect to AAVs, the term "isolated" refers to an AAV that has been artificially produced or obtained. Isolated AAVs may be produced using recombinant methods. Such AAVs are referred to herein as "recombinant AAVs". Recombinant AAVs (rAAVs) preferably have tissue-specific targeting capabilities, such that a nuclease and/or transgene of the rAAV will be delivered specifically to one or more predetermined tissue(s). The AAV capsid is an important element in determining these tissue-specific targeting capabilities. Thus, an rAAV having a capsid appropriate for the tissue being targeted can be selected. In some aspects, the disclosure provides an rAAV having a capsid appropriate for targeting prostate tissue. In some embodiments, the capsid has a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO. In some embodiments, the capsid has an AAV6.2 serotype (e.g. , SEQ ID NO: 3) or an AAV7 serotype (e.g. , SEQ ID NO: 4). The skilled artisan also recognizes that rAAV described herein may comprise variants of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO serotype capsid proteins. In some embodiments, the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7.
Methods for obtaining recombinant AAVs having a desired capsid protein are well known in the art. (See, for example, US 2003/0138772), the contents of which are
incorporated herein by reference in their entirety). Typically the methods involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein; a functional rep gene; a recombinant AAV vector composed of, AAV inverted terminal repeats (ITRs) and a transgene; and sufficient helper functions to permit packaging of the
recombinant AAV vector into the AAV capsid proteins. In some embodiments, capsid proteins are structural proteins encoded by the cap gene of an AAV. AAVs comprise three capsid proteins, virion proteins 1 to 3 (named VP1, VP2 and VP3), all of which are transcribed from a single cap gene via alternative splicing. In some embodiments, the molecular weights of VP1, VP2 and VP3 are respectively about 87 kDa, about 72 kDa and about 62 kDa. In some embodiments, upon translation, capsid proteins form a spherical 60- mer protein shell around the viral genome. In some embodiments, the functions of the capsid proteins are to protect the viral genome, deliver the genome and interact with the host. In some aspects, capsid proteins deliver the viral genome to a host in a tissue specific manner.
The components to be cultured in the host cell to package a rAAV vector in an AAV capsid may be provided to the host cell in trans. Alternatively, any one or more of the required components (e.g. , recombinant AAV vector, rep sequences, cap sequences, and/or helper functions) may be provided by a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art. Most suitably, such a stable host cell will contain the required component(s) under the control of an inducible promoter. However, the required component(s) may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene. In still another alternative, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters. For example, a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contain the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
In some embodiments, the instant disclosure relates to a host cell containing a nucleic acid that comprises a coding sequence encoding a gene associated with a prostate disease. In some embodiments, the instant disclosure relates to a composition comprising the host cell described above. In some embodiments, the composition comprising the host cell above further comprises a cryopreservative.
The recombinant AAV vector, rep sequences, cap sequences, and helper functions required for producing the rAAV of the disclosure may be delivered to the packaging host cell using any appropriate genetic element (vector). The selected genetic element may be delivered by any suitable method, including those described herein. The methods used to construct any embodiment of this disclosure are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g. , Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present disclosure. See, e.g. , K. Fisher et al, J. Virol., 70:520-532 (1993) and U.S. Pat. No. 5,478,745.
In some embodiments, recombinant AAVs may be produced using the triple transfection method (described in detail in U.S. Pat. No. 6,001,650). Typically, the recombinant AAVs are produced by transfecting a host cell with an recombinant AAV vector (comprising a transgene) to be packaged into AAV particles, an AAV helper function vector, and an accessory function vector. An AAV helper function vector encodes the "AAV helper function" sequences (i.e. , rep and cap), which function in trans for productive AAV replication and encapsidation. Preferably, the AAV helper function vector supports efficient AAV vector production without generating any detectable wild-type AAV virions (i.e. , AAV virions containing functional rep and cap genes). Non-limiting examples of vectors suitable for use with the present disclosure include pHLP19, described in U.S. Pat. No. 6,001,650 and pRep6cap6 vector, described in U.S. Pat. No. 6,156,303, the entirety of both incorporated by reference herein. The accessory function vector encodes nucleotide sequences for non-AAV derived viral and/or cellular functions upon which AAV is dependent for replication (i.e., "accessory functions"). The accessory functions include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid assembly. Viral-based accessory functions can be derived from any of the known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type-1), and vaccinia virus.
In some aspects, the disclosure provides transfected host cells. The term
"transfection" is used to refer to the uptake of foreign DNA by a cell, and a cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13: 197. Such techniques can be used to introduce one or more exogenous nucleic acids, such as a nucleotide integration vector and other nucleic acid molecules, into suitable host cells.
A "host cell" refers to any cell that harbors, or is capable of harboring, a substance of interest. Often a host cell is a mammalian cell. A host cell may be used as a recipient of an AAV helper construct, an AAV minigene plasmid, an accessory function vector, or other transfer DNA associated with the production of recombinant AAVs. The term includes the progeny of the original cell which has been transfected. Thus, a "host cell" as used herein may refer to a cell which has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
As used herein, the term "cell line" refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants.
As used herein, the terms "recombinant cell" refers to a cell into which an exogenous DNA segment, such as DNA segment that leads to the transcription of a biologically-active polypeptide or production of a biologically active nucleic acid such as an RNA, has been introduced.
As used herein, the term "vector" includes any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors. In some embodiments, useful vectors are contemplated to be those vectors in which the nucleic acid segment to be transcribed is positioned under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrases "operatively positioned," "under control" or "under transcriptional control" means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. The term "expression vector or construct" means any type of genetic construct containing a nucleic acid in which part or all of the nucleic acid encoding sequence is capable of being transcribed. In some embodiments, expression includes transcription of the nucleic acid, for example, to generate a biologically-active polypeptide product or functional RNA (e.g., guide RNA) from a transcribed gene.
The foregoing methods for packaging recombinant vectors in desired AAV capsids to produce the rAAVs of the disclosure are not meant to be limiting and other suitable methods will be apparent to the skilled artisan.
Isolated Nucleic Acids
A "nucleic acid" sequence refers to a DNA or RNA sequence. In some embodiments, proteins and nucleic acids of the disclosure are isolated. As used herein, the term "isolated" means artificially produced. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. As used herein with respect to proteins or peptides, the term "isolated" refers to a protein or peptide that has been isolated from its natural environment or artificially produced (e.g., by chemical synthesis, by recombinant DNA technology, etc.).
The skilled artisan will also realize that conservative amino acid substitutions may be made to provide functionally equivalent variants, or homologs of the capsid proteins. In some aspects the disclosure embraces sequence alterations that result in conservative amino acid substitutions. As used herein, a conservative amino acid substitution refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references that compile such methods, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made among amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. Therefore, one can make conservative amino acid substitutions to the amino acid sequence of the proteins and polypeptides disclosed herein.
Recombinant AAV Vectors (rAAV Vectors)
"Recombinant AAV (rAAV) vectors" of the disclosure are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). It is this recombinant AAV vector which is packaged into a capsid protein and delivered to a selected target cell. In some embodiments, the transgene is a nucleic acid sequence, heterologous to the vector sequences, which encodes a polypeptide, protein, functional RNA molecule (e.g. , gRNA) or other gene product, of interest. The nucleic acid coding sequence is operatively linked to regulatory components in a manner which permits transgene transcription, translation, and/or expression in a cell of a target tissue.
In some embodiments, the instant disclosure relates to a recombinant AAV (rAAV) vector comprising a nucleic acid sequence including a promoter operably linked to a transgene, wherein the transgene is a gene associated with a prostate disease. In some embodiments, a rAAV vector further comprises nucleic acid sequences encoding one or more AAV inverted terminal repeat sequences (ITRs), for example AAV2 ITRs. In some embodiments, a rAAV vector further comprises nucleic acid sequences encoding one or more AAV ITRs selected from the group consisting of AAV3, AAV4, AAV5, and AAV6.
The AAV sequences of the vector typically comprise the cis-acting 5' and 3' inverted terminal repeat sequences (See, e.g. , B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp. 155 168 (1990)). The ITR sequences are about 145 bp in length. Preferably, substantially the entire sequences encoding the ITRs are used in the molecule, although some degree of minor modification of these sequences is permissible. The ability to modify these ITR sequences is within the skill of the art. (See, e.g. , texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996)). An example of such a molecule employed in the present disclosure is a "cis-acting" plasmid containing the transgene, in which the selected transgene sequence and associated regulatory elements are flanked by the 5' and 3' AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including presently identified mammalian AAV types (e.g. , AAV2, AAV3, AAV4, AAV5, or AAV6 ITR sequences).
In addition to the major elements identified above for the recombinant AAV vector, the vector also includes control elements necessary which are operably linked to the transgene in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector or infected with the virus produced by the disclosure. As used herein, "operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e. , Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. A great number of expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.
As used herein, a nucleic acid sequence (e.g. , coding sequence) and regulatory sequences are said to be "operably" linked when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequences. If it is desired that the nucleic acid sequences be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame- shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. Similarly two or more coding regions are operably linked when they are linked in such a way that their transcription from a common promoter results in the expression of two or more proteins having been translated in frame. In some embodiments, operably linked coding sequences yield a fusion protein. In some embodiments, operably linked coding sequences yield a functional RNA (e.g. , gRNA).
For nucleic acids encoding proteins, a polyadenylation sequence generally is inserted following the transgene sequences and before the 3' AAV ITR sequence. A rAAV construct useful in the present disclosure may also contain an intron, desirably located between the promoter/enhancer sequence and the transgene. One possible intron sequence is derived from SV-40, and is referred to as the SV-40 T intron sequence. Another vector element that may be used is an internal ribosome entry site (IRES). An IRES sequence is used to produce more than one polypeptide from a single gene transcript. An IRES sequence would be used to produce a protein that contain more than one polypeptide chains. Selection of these and/or other vector elements may be performed, as appropriate, and many such sequences are available [see, e.g. , Sambrook et al, and references cited therein at, for example, pages 3.18 3.26 and 16.17 16.27 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989] . In some embodiments, a Foot and Mouth Disease Virus 2A sequence is included in polyprotein; this is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of polyproteins (Ryan, M D et al., EMBO, 1994; 4: 928-933; Mattion, N M et al., J Virology, November 1996; p. 8124-8127; Furler, S et al., Gene Therapy, 2001 ; 8: 864-873; and Halpin, C et al., The Plant Journal, 1999; 4: 453-459). The cleavage activity of the 2A sequence has previously been
demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and retroviruses) (Ryan, M D et al., EMBO, 1994; 4: 928-933; Mattion, N M et al., J Virology, November 1996; p. 8124-8127; Furler, S et al., Gene Therapy, 2001 ; 8: 864-873; and Halpin, C et al., The Plant Journal, 1999; 4: 453-459; de Felipe, P et al., Gene Therapy, 1999; 6: 198- 208; de Felipe, P et al., Human Gene Therapy, 2000; 11 : 1921- 1931.; and Klump, H et al., Gene Therapy, 2001 ; 8: 811-817).
The precise nature of the regulatory sequences needed for gene expression in host cells may vary between species, tissues or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, enhancer elements, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region that includes a promoter sequence for
transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the disclosure may optionally include 5' leader or signal sequences. The choice and design of an
appropriate vector is within the ability and discretion of one of ordinary skill in the art.
Examples of constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the
cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g. , Boshart et al, Cell, 41 :521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β- actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter
[Invitrogen] . In some embodiments, a promoter is an enhanced chicken β-actin promoter. Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g. , acute phase, a particular differentiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art. Examples of inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex) -inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088); the ecdysone insect promoter (No et al, Proc. Natl. Acad. Sci. USA, 93:3346- 3351 (1996)), the tetracycline-repressible system (Gossen et al, Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline-inducible system (Gossen et al, Science, 268: 1766- 1769 (1995), see also Harvey et al, Curr. Opin. Chem. Biol., 2:512-518 (1998)), the RU486- inducible system (Wang et al, Nat. Biotech., 15:239-243 (1997) and Wang et al, Gene Ther., 4:432-441 (1997)) and the rapamycin-inducible system (Magari et al, J. Clin. Invest.,
100:2865-2872 (1997)). Still other types of inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g. , temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.
In another embodiment, the native promoter for the transgene will be used. The native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression. The native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue- specific manner, or in response to specific transcriptional stimuli. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.
In some embodiments, the regulatory sequences impart tissue- specific gene expression capabilities. In some cases, the tissue-specific regulatory sequences bind tissue- specific transcription factors that induce transcription in a tissue specific manner. Such tissue-specific regulatory sequences (e.g. , promoters, enhancers, etc..) are well known in the art. Exemplary tissue- specific regulatory sequences include, but are not limited to the following tissue specific promoters: a liver- specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin promoter, a pancreatic polypeptide (PPY) promoter, a synapsin-1 (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a a-myosin heavy chain (a-MHC) promoter, or a cardiac Troponin T (cTnT) promoter. Other exemplary promoters include Beta-actin promoter, hepatitis B virus core promoter, Sandig et al., Gene Ther., 3: 1002-9 (1996); alpha-fetoprotein (AFP) promoter, Arbuthnot et al., Hum. Gene Ther., 7: 1503-14 (1996)), bone osteocalcin promoter (Stein et al., Mol. Biol. Rep., 24: 185-96 (1997)); bone sialoprotein promoter (Chen et al., J. Bone Miner. Res., 11:654-64 (1996)), CD2 promoter (Hansal et al., J. Immunol., 161: 1063-8 (1998); immunoglobulin heavy chain promoter; T cell receptor a-chain promoter, neuronal such as neuron- specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., 13:503-15 (1993)), neurofilament light-chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron- specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)), among others which will be apparent to the skilled artisan. In some embodiments, the promoter is a prostate- specific promoter, for example a prostate-specific antigen (PSA) promoter, a probasin promoter, a Moloney murine leukemia virus long terminal repeat (MMTV LTR) promoter, etc.
In some embodiments, one or more bindings sites for one or more of miRNAs are incorporated in a transgene of a rAAV vector, to inhibit the expression of the transgene in one or more tissues of an subject harboring the transgene. The skilled artisan will appreciate that binding sites may be selected to control the expression of a transgene in a tissue specific manner. For example, binding sites for the liver- specific miR-122 may be incorporated into a transgene to inhibit expression of that transgene in the liver. The target sites in the mRNA may be in the 5' UTR, the 3' UTR or in the coding region. Typically, the target site is in the 3' UTR of the mRNA. Furthermore, the transgene may be designed such that multiple miRNAs regulate the mRNA by recognizing the same or multiple sites. The presence of multiple miRNA binding sites may result in the cooperative action of multiple RISCs and provide highly efficient inhibition of expression. The target site sequence may comprise a total of 5-100, 10-60, or more nucleotides. The target site sequence may comprise at least 5 nucleotides of the sequence of a target gene binding site. miRNAs In some aspects, the disclosure relates to delivery of a transgene encoding microRNA 34a (miR34a) to a cell. miRNAs are natively expressed, typically as final 19-25 non- translated RNA products. miRNAs exhibit their activity through sequence- specific interactions with the 3' untranslated regions (UTR) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors which are subsequently processed into a miRNA duplex, and further into a "mature" single stranded miRNA molecule. This mature miRNA guides a multiprotein complex, miRISC, which identifies target site, e.g. , in the 3' UTR regions, of target mRNAs based upon their complementarity to the mature miRNA.
Without wishing to be bound by any particular theory, miR34a is known to function as a regulator of tumor suppression in cells. Accordingly, in some embodiments, delivery of a transgene encoding miR34a to a cell is useful for treatment of certain diseases characterized by reduction of miR34a expression or activity (e.g. , certain cancers). Examples of cancers characterized by a reduction of miR34a expression or activity include but are not limited to prostate cancer, pancreatic cancer, breast cancer, colorectal cancer, cervical cancer, certain brain cancers (e.g. , glioblastoma, medulloblastoma, etc.). In some embodiments, miR34a regulates cancer stem cells, such as prostate cancer stem cells, lung cancer stem cells, etc. , for example as described in Misso et al. (2014) Mol. Ther. Nucleic Acids 3, el94;
doi: 10.1038/mtna.2014.47.
Thus, in some embodiments, the disclosure provides a method for treating cancer, the method comprising delivering a transgene encoding miR34a to a subject having a cancer characterized by a reduction in mir34a expression or activity.
In some aspects, the disclosure relates to the discovery that overexpression of certain miRNAs (e.g. , miR34a) reduces prostate cancer cell viability and cell migration.
Accordingly, in some aspects, the disclosure provides methods and compositions for treating prostate cancer by overexpressing miRNAs (e.g. , miR34a) in a subject in need thereof.
miRNAs and other small interfering nucleic acids regulate gene expression via target RNA transcript cleavage/degradation or translational repression of the target messenger RNA (mRNA).
In some embodiments, a miR34a miRNA described by the disclosure comprises or consists of a nucleic acid sequence as set forth in SEQ ID NO: 15. Variants of SEQ ID NO: 15 are also contemplated by the disclosure. For example, in some embodiments, a miR34a sequence is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 15.
It should be appreciated that, in some embodiments, a miR34a miRNA is an inhibitory nucleic acid (e.g., miRNA, pri-miRNA, amiRNA, dsRNA, shRNA, siRNA, etc.) that is complementary with and specifically binds to a target site sequence (e.g., a miR34a binding site) of a gene (e.g., CCND1, TOP2A, CD44, etc.) and inhibits expression of the target sequence (e.g., inhibits transcription, translation, or production a protein encoded by the target sequence). In some embodiments, a target sequence comprises at least 5 contiguous nucleotides that are complementary with a sequence as set forth in SEQ ID NO: 15.
Recombinant AAV Administration Methods
The rAAVs may be delivered to a subject in compositions according to any appropriate methods known in the art. The rAAV, preferably suspended in a physiologically compatible carrier (i.e., in a composition), may be administered to a subject, i.e. host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate (e.g., Macaque). In some embodiments, a host animal does not include a human.
Delivery of the rAAVs to a mammalian subject may be by, for example, intraprostate injection. In some embodiments, the intraprostate injection is transperineal, transrectal, or transurethral injection. In some embodiments, the injection is not intraperitoneal injection
(i.p.).
The compositions of the disclosure may comprise an rAAV alone, or in combination with one or more other viruses (e.g., a second rAAV encoding having one or more different transgenes). In some embodiments, a composition comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different rAAVs each having one or more different transgenes.
In some embodiments, a composition further comprises a pharmaceutically acceptable carrier. Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the rAAV is directed. For example, one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present disclosure.
Optionally, the compositions of the disclosure may contain, in addition to the rAAV and carrier(s), other pharmaceutical ingredients, such as preservatives, or chemical stabilizers. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Suitable chemical stabilizers include gelatin and albumin.
The rAAVs are administered in sufficient amounts to transfect the cells of a desired tissue (e.g. , prostate tissue) and to provide sufficient levels of gene transfer and expression without undue adverse effects. Examples of pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the selected organ (e.g. , intraprostate delivery to the prostate), oral, inhalation (including intranasal and intratracheal delivery), intraocular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parental routes of administration. Routes of administration may be combined, if desired.
The dose of rAAV virions required to achieve a particular "therapeutic effect," e.g. , the units of dose in genome copies/per kilogram of body weight (GC/kg), will vary based on several factors including, but not limited to: the route of rAAV virion administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determine a rAAV virion dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors.
An effective amount of an rAAV is an amount sufficient to target infect an animal, target a desired tissue. In some embodiments, an effective amount of an rAAV is an amount sufficient to produce a stable somatic transgenic animal model. The effective amount will depend primarily on factors such as the species, age, weight, health of the subject, and the tissue to be targeted, and may thus vary among animal and tissue. For example, an effective amount of the rAAV is generally in the range of from about 1 ml to about 100 ml of solution containing from about 109 to 1016 genome copies. In some cases, a dosage between about
11 13 11 12 10 to 10 rAAV genome copies is appropriate. In certain embodiments, 10 or 10 rAAV genome copies is effective to target prostate tissue. In some cases, stable transgenic animals are produced by multiple doses of an rAAV. In some embodiments, a dose of rAAV is administered to a subject no more than once per calendar day (e.g. , a 24-hour period). In some embodiments, a dose of rAAV is administered to a subject no more than once per 2, 3, 4, 5, 6, or 7 calendar days. In some embodiments, a dose of rAAV is administered to a subject no more than once per calendar week (e.g. , 7 calendar days). In some embodiments, a dose of rAAV is administered to a subject no more than bi-weekly (e.g. , once in a two calendar week period). In some embodiments, a dose of rAAV is administered to a subject no more than once per calendar month (e.g. , once in 30 calendar days). In some embodiments, a dose of rAAV is
administered to a subject no more than once per six calendar months. In some embodiments, a dose of rAAV is administered to a subject no more than once per calendar year (e.g. , 365 days or 366 days in a leap year).
In some embodiments, rAAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high rAAV concentrations are present
13
(e.g. , -10 GC/ml or more). Appropriate methods for reducing aggregation of may be used, including, for example, addition of surfactants, pH adjustment, salt concentration adjustment, etc. (See, e.g. , Wright FR, et al., Molecular Therapy (2005) 12, 171-178, the contents of which are incorporated herein by reference.)
Formulation of pharmaceutically-acceptable excipients and carrier solutions is well- known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens. Typically, these formulations may contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation. Naturally, the amount of active compound in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility,
bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
In some embodiments, rAAVs in suitably formulated pharmaceutical compositions disclosed herein are delivered directly to target tissue, e.g., direct to prostate tissue. However, in certain circumstances it may be desirable to separately or in addition deliver the rAAV-based therapeutic constructs via another route, e.g., subcutaneously,
intraopancreatically, intranasally, parenterally, intravenously, intramuscularly, intrathecally, or orally, intraperitoneally, or by inhalation. In some embodiments, the administration modalities as described in U.S. Pat. Nos. 5,543,158; 5,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety) may be used to deliver rAAVs. In some embodiments, a preferred mode of administration is by intraprostate injection.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In many cases the form is sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. , glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For administration of an injectable aqueous solution, for example, the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a suitable sterile aqueous medium may be employed. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the appropriate dose for the individual host.
Sterile injectable solutions are prepared by incorporating the active rAAV in the required amount in the appropriate solvent with various of the other ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
The rAAV compositions disclosed herein may also be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the compositions. The phrase
"pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a host.
Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present disclosure into suitable host cells. In particular, the rAAV vector delivered trangenes may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.
Such formulations may be preferred for the introduction of pharmaceutically acceptable formulations of the nucleic acids or the rAAV constructs disclosed herein. The formation and use of liposomes is generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed.
Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 μιη. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 .ANG., containing an aqueous solution in the core.
Alternatively, nanocapsule formulations of the rAAV may be used. Nanocapsules can generally entrap substances in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μιη) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use.
Kits and Related Compositions
The agents described herein may, in some embodiments, be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic or research applications. A kit may include one or more containers housing the components of the disclosure and instructions for use. Specifically, such kits may include one or more agents described herein, along with instructions describing the intended application and the proper use of these agents. In certain embodiments agents in a kit may be in a
pharmaceutical formulation and dosage suitable for a particular application and for a method of administration of the agents. Kits for research purposes may contain the components in appropriate concentrations or quantities for running various experiments.
In some embodiments, the instant disclosure relates to a kit for producing a rAAV, the kit comprising a container housing an isolated nucleic acid encoding an AAV capsid protein selected from any one of SEQ ID NO: 1-7. In some embodiments, the kit further comprises instructions for producing the rAAV. In some embodiments, the kit further comprises at least one container housing a recombinant AAV vector, wherein the recombinant AAV vector comprises a transgene (e.g. , a gene associated with prostate disease).
In some embodiments, the instant disclosure relates to a kit comprising a container housing a recombinant AAV having an isolated AAV capsid protein having an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
The kit may be designed to facilitate use of the methods described herein by researchers and can take many forms. Each of the compositions of the kit, where applicable, may be provided in liquid form (e.g. , in solution), or in solid form, (e.g. , a dry powder). In certain cases, some of the compositions may be constitutable or otherwise processable (e.g. , to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit. As used herein, "instructions" can define a component of instruction and/or promotion, and typically involve written instructions on or associated with packaging of the disclosure.
Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g. , videotape, DVD, etc.), Internet, and/or web-based
communications, etc. The written instructions may be in a form prescribed by a
governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for animal administration.
The kit may contain any one or more of the components described herein in one or more containers. As an example, in one embodiment, the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject. The kit may include a container housing agents described herein. The agents may be in the form of a liquid, gel or solid (powder). The agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other container for storage. A second container may have other agents prepared sterilely. Alternatively the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container. The kit may have one or more or all of the components required to administer the agents to an animal, such as a syringe, topical application devices, or iv needle tubing and bag, particularly in the case of the kits for producing specific somatic animal models.
The kit may have a variety of forms, such as a blister pouch, a shrink wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box or a bag. The kit may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped. The kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. The kit may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration etc.
The instructions included within the kit may involve methods for detecting a latent AAV in a cell. In addition, kits of the disclosure may include, instructions, a negative and/or positive control, containers, diluents and buffers for the sample, sample preparation tubes and a printed or electronic table of reference AAV sequence for sequence comparisons.
Sequences
> AAV5 capsid protein amino acid sequence (SEQ ID NO: 1)
MSFVDHPPDWLEEVGEGLREFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGPGN GLDRGEPVNRADEVAREHDISYNEQLEAGDNPYLKYNHADAEFQEKLADDTSFGGN LGKAVFQAKKRVLEPFGLVEEGAKTAPTGKRIDDHFPKRKKARTEEDSKPSTSSDAE AGPSGSQQLQIPAQPASSLGADTMSAGGGGPLGDNNQGADGVGNASGDWHCDSTW MGDR V VTKS TRT W VLPS YNNHQ YREIKS GS VDGS N AN A YFG YS TPWG YFDFNRFHS HWSPRDWQRLINNYWGFRPRSLRVKIFNIQVKEVTVQDSTTTIANNLTSTVQVFTDD DYQLPYVVGNGTEGCLPAFPPQVFTLPQYGYATLNRDNTENPTERSSFFCLEYFPSK
MLRTGNNFEFTYNFEE VPFHS SFAPS QNLFKLANPLVDQYLYRFVS TNNTGGVQFNK
NLAGRYANTYKNWFPGPMGRTQGWNLGSGVNRASVSAFATTNRMELEGASYQVPP
QPNGMTNNLQGSNTYALENTMIFNSQPANPGTTATYLEGNMLITSESETQPVNRVAY
NVGGQMATNNQSSTTAPATGTYNLQEIVPGSVWMERDVYLQGPIWAKIPETGAHFH
PS P AMGGFGLKHPPPMMLIKNTP VPGNITS FS D VP VS S FI Q YS TGQ VT VEMEWELKK
ENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL
>AAV6 capsid protein amino acid sequence (SEQ ID NO: 2)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLG
PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTS
FGGNLGRA VFQAKKRVLEPFGLVEEGAKT APGKKRPVEQSPQEPDS S S GIGKTGQQP
AKKRLNFGQTGDSESVPDPQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGV
GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYS
TPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIA
NNLTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRS
SFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLNRT
QNQS GS AQNKDLLFS RGS P AGMS VQPKNWLPGPC YRQQR VS KTKTDNNNS NFT WT
GASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTALDNVMIT
DEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG
ΡΓ\ν AKIPHTDGHFHPS PLMGGFGLKHPPPQILIKNTP VP ANPP AEFS ATKF AS FITQ YS T
GQVSVEIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYL
TRPL
>AAV6.2 capsid protein amino acid sequence (SEQ ID NO: 3)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLG
PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTS
FGGNLGRA VFQAKKRVLEPLGLVEEGAKT APGKKRPVEQSPQEPDS S S GIGKTGQQP
AKKRLNFGQTGDSESVPDPQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGV
GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYS
TPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIA
NNLTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRS
SFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLNRT
QNQS GS AQNKDLLFS RGS P AGMS VQPKNWLPGPC YRQQR VS KTKTDNNNS NFT WT
GASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTALDNVMIT
DEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG
ΡΓ\ν AKIPHTDGHFHPS PLMGGFGLKHPPPQILIKNTP VP ANPP AEFS ATKF AS FITQ YS T
GQVSVEIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYL
TRPL
>AAV7 capsid protein amino acid sequence (SEQ ID NO: 4)
MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLG
PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTS
FGGNLGRA VFQAKKRVLEPLGLVEEGAKT APAKKRPVEPSPQRSPDSSTGIGKKGQQ
PARKRLNFGQTGDSESVPDPQPLGEPPAAPSSVGSGTVAAGGGAPMADNNEGADGV
GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSETAGSTNDNTYFGYS
TPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLRFKLFNIQVKEVTTNDGVTTIA
NNLTS TIQ VFS DS E YQLP Y VLGS AHQGCLPPFP AD VFMIPQ YG YLTLNNGS QS VGRS S FYCLE YFPS QMLRTGNNFEFS YS FED VPFHS S Y AHS QS LDRLMNPLID Q YL Y YLARTQ
SNPGGTAGNRELQFYQGGPSTMAEQAKNWLPGPCFRQQRVSKTLDQNNNSNFAWT
GATKYHLNGRNSLVNPGVAMATHKDDEDRFFPSSGVLIFGKTGATNKTTLENVLMT
NEEEIRPTNPVATEEYGIVSSNLQAANTAAQTQVVNNQGALPGMVWQNRDVYLQGP
IWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPANPPEVFTPAKFASFITQYSTG
QVSVEIEWELQKENSKRWNPEIQYTSNFEKQTGVDFAVDSQGVYSEPRPIGTRYLTR
NL
>AAV8 capsid protein amino acid sequence (SEQ ID NO: 5)
MAADGYLPDWLEDNLSEGIREWWALKPGAPKPKANQQKQDDGRGLVLPGYKYLG
PFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTS
FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQ
PARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGPNTMAAGGGAPMADNNEGADG
VGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFG
YSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKT
IANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR
SSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSR
TQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAW
TAGTKYHLNGRNSLANPGIAMATHKDDEERFFPSNGILIFGKQNAARDNADYSDVM
LTSEEEIKTTNPVATEEYGIVADNLQQQNTAPQIGTVNSQGALPGMVWQNRDVYLQ
GPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQSKLNSFITQYS
TGQ VS VEIE WELQKENS KRWNPEIQ YTS N Y YKS TS VDF A VNTEG V YS EPRPIGTRYL
TRNL
>AAV9 capsid protein amino acid sequence (SEQ ID NO: 6)
MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLG
PGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTS
FGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQP
AKKRLNFGQTGDTES VPDPQPIGEPPAAPS GVGS LTMAS GGGAPVADNNEGADGVG
S S S GNWHCDS QWLGDRVITTS TRTW ALPT YNNHLYKQIS NSTSGGSS NDN A YFG YS T
PWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIA
NNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRS
S FYCLE YFPS QMLRTGNNFQFS YEFEN VPFHS S Y AHS QS LDRLMNPLIDQ YLY YLS KT
INGS GQNQQTLKFS V AGPS NM A VQGRN YIPGPS YRQQR VS TT VTQNNNS EF AWPG A
SSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITN
EEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGP
IWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYST
GQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLT
RNL
>AAVrh. lO capsid protein amino acid sequence (SEQ ID NO: 7) MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLG PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTS FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQ PAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGAPMADNNEGADGV GS S S GNWHCDS TWLGDR VITTS TRT W ALPT YNNHLYKQIS NGTS GGS TNDNT YFG Y STPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTI ANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR S S FYCLE YFPS QMLRTGNNFEFS YQFED VPFHS S Y AHS QS LDRLMNPLIDQ YLY YLS R TQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAW TGATKYHLNGRDS LVNPGVAM ATHKDDEERFFPS S GVLMFGKQGAGKDNVD YS S V MLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVY LQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFSQAKLASFIT Q YS TGQ VS VEIE WELQKENS KRWNPEIQ YTS N Y YKS TN VDFA VNTDGT YS EPRPIGT RYLTRNL
> AAV5 capsid protein nucleic acid sequence (SEQ ID NO: 8)
ATGTCTTTTGTTGATCACCCTCCAGATTGGTTGGAAGAAGTTGGTGAAGGTCTTC GCGAGTTTTTGGGCCTTGAAGCGGGCCCACCGAAACCAAAACCCAATCAGCAGC ATCAAGATCAAGCCCGTGGTCTTGTGCTGCCTGGTTATAACTATCTCGGACCCGG AAACGGTCTCGATCGAGGAGAGCCTGTCAACAGGGCAGACGAGGTCGCGCGAGA GCACGACATCTCGTACAACGAGCAGCTTGAGGCGGGAGACAACCCCTACCTCAA GTACAACCACGCGGACGCCGAGTTTCAGGAGAAGCTCGCCGACGACACATCCTT CGGGGGAAACCTCGGAAAGGCAGTCTTTCAGGCCAAGAAAAGGGTTCTCGAACC TTTTGGCCTGGTTGAAGAGGGTGCTAAGACGGCCCCTACCGGAAAGCGGATAGA CGACCACTTTCCAAAAAGAAAGAAGGCCCGGACCGAAGAGGACTCCAAGCCTTC CACCTCGTCAGACGCCGAAGCTGGACCCAGCGGATCCCAGCAGCTGCAAATCCC AGCCCAACCAGCCTCAAGTTTGGGAGCTGATACAATGTCTGCGGGAGGTGGCGG CCCATTGGGCGACAATAACCAAGGTGCCGATGGAGTGGGCAATGCCTCGGGAGA TTGGCATTGCGATTCCACGTGGATGGGGGACAGAGTCGTCACCAAGTCCACCCG AACCTGGGTGCTGCCCAGCTACAACAACCACCAGTACCGAGAGATCAAAAGCGG CTCCGTCGACGGAAGCAACGCCAACGCCTACTTTGGATACAGCACCCCCTGGGG GTACTTTGACTTTAACCGCTTCCACAGCCACTGGAGCCCCCGAGACTGGCAAAGA CTCATCAACAACTACTGGGGCTTCAGACCCCGGTCCCTCAGAGTCAAAATCTTCA ACATTCAAGTCAAAGAGGTCACGGTGCAGGACTCCACCACCACCATCGCCAACA ACCTCACCTCCACCGTCCAAGTGTTTACGGACGACGACTACCAGCTGCCCTACGT CGTCGGCAACGGGACCGAGGGATGCCTGCCGGCCTTCCCTCCGCAGGTCTTTACG CTGCCGCAGTACGGTTACGCGACGCTGAACCGCGACAACACAGAAAATCCCACC GAGAGGAGCAGCTTCTTCTGCCTAGAGTACTTTCCCAGCAAGATGCTGAGAACG GGCAACAACTTTGAGTTTACCTACAACTTTGAGGAGGTGCCCTTCCACTCCAGCT TCGCTCCCAGTCAGAACCTCTTCAAGCTGGCCAACCCGCTGGTGGACCAGTACTT GTACCGCTTCGTGAGCACAAATAACACTGGCGGAGTCCAGTTCAACAAGAACCT GGCCGGGAGATACGCCAACACCTACAAAAACTGGTTCCCGGGGCCCATGGGCCG AACCCAGGGCTGGAACCTGGGCTCCGGGGTCAACCGCGCCAGTGTCAGCGCCTT CGCCACGACCAATAGGATGGAGCTCGAGGGCGCGAGTTACCAGGTGCCCCCGCA GCCGAACGGCATGACCAACAACCTCCAGGGCAGCAACACCTATGCCCTGGAGAA CACTATGATCTTCAACAGCCAGCCGGCGAACCCGGGCACCACCGCCACGTACCTC GAGGGCAACATGCTCATCACCAGCGAGAGCGAGACGCAGCCGGTGAACCGCGTG GCGTACAACGTCGGCGGGCAGATGGCCACCAACAACCAGAGCTCCACCACTGCC CCCGCGACCGGCACGTACAACCTCCAGGAAATCGTGCCCGGCAGCGTGTGGATG GAGAGGGACGTGTACCTCCAAGGACCCATCTGGGCCAAGATCCCAGAGACGGGG GCGCACTTTCACCCCTCTCCGGCCATGGGCGGATTCGGACTCAAACACCCACCGC CCATGATGCTCATCAAGAACACGCCTGTGCCCGGAAATATCACCAGCTTCTCGGA CGTGCCCGTCAGCAGCTTCATCACCCAGTACAGCACCGGGCAGGTCACCGTGGA GATGGAGTGGGAGCTCAAGAAGGAAAACTCCAAGAGGTGGAACCCAGAGATCC AGTACACAAACAACTACAACGACCCCCAGTTTGTGGACTTTGCCCCGGACAGCA CCGGGGAATACAGAACCACCAGACCTATCGGAACCCGATACCTTACCCGACCCC TT
> AAV6 capsid nucleic acid sequence (SEQ ID NO: 9)
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCA TTCGCGAGTGGTGGGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGC AAAAGCAGGACGACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGAC CCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCGGATGCAGCGGCCC TCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACC TGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGT CTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGAGGGTTCTCG AACCTTTTGGTCTGGTTGAGGAAGGTGCTAAGACGGCTCCTGGAAAGAAACGTC CGGTAGAGCAGTCGCCACAAGAGCCAGACTCCTCCTCGGGCATTGGCAAGACAG GCCAGCAGCCCGCTAAAAAGAGACTCAATTTTGGTCAGACTGGCGACTCAGAGT CAGTCCCCGACCCACAACCTCTCGGAGAACCTCCAGCAACCCCCGCTGCTGTGGG ACCTACTACAATGGCTTCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGG CGCCGACGGAGTGGGTAATGCCTCAGGAAATTGGCATTGCGATTCCACATGGCT GGGCGACAGAGTCATCACCACCAGCACCCGAACATGGGCCTTGCCCACCTATAA CAACCACCTCTACAAGCAAATCTCCAGTGCTTCAACGGGGGCCAGCAACGACAA CCACTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGATTTCAACAGATTCCAC TGCCATTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAATTGGGGATTCC GGCCCAAGAGACTCAACTTCAAGCTCTTCAACATCCAAGTCAAGGAGGTCACGA CGAATGATGGCGTCACGACCATCGCTAATAACCTTACCAGCACGGTTCAAGTCTT CTCGGACTCGGAGTACCAGTTGCCGTACGTCCTCGGCTCTGCGCACCAGGGCTGC CTCCCTCCGTTCCCGGCGGACGTGTTCATGATTCCGCAGTACGGCTACCTAACGC TCAACAATGGCAGCCAGGCAGTGGGACGGTCATCCTTTTACTGCCTGGAATATTT CCCATCGCAGATGCTGAGAACGGGCAATAACTTTACCTTCAGCTACACCTTCGAG GACGTGCCTTTCCACAGCAGCTACGCGCACAGCCAGAGCCTGGACCGGCTGATG AATCCTCTCATCGACCAGTACCTGTATTACCTGAACAGAACTCAGAATCAGTCCG GAAGTGCCCAAAACAAGGACTTGCTGTTTAGCCGGGGGTCTCCAGCTGGCATGTC TGTTCAGCCCAAAAACTGGCTACCTGGACCCTGTTACCGGCAGCAGCGCGTTTCT AAAACAAAAACAGACAACAACAACAGCAACTTTACCTGGACTGGTGCTTCAAAA TATAACCTTAATGGGCGTGAATCTATAATCAACCCTGGCACTGCTATGGCCTCAC ACAAAGACGACAAAGACAAGTTCTTTCCCATGAGCGGTGTCATGATTTTTGGAAA GGAGAGCGCCGGAGCTTCAAACACTGCATTGGACAATGTCATGATCACAGACGA AGAGGAAATCAAAGCCACTAACCCCGTGGCCACCGAAAGATTTGGGACTGTGGC AGTCAATCTCCAGAGCAGCAGCACAGACCCTGCGACCGGAGATGTGCATGTTAT GGGAGCCTTACCTGGAATGGTGTGGCAAGACAGAGACGTATACCTGCAGGGTCC TATTTGGGCCAAAATTCCTCACACGGATGGACACTTTCACCCGTCTCCTCTCATG GGCGGCTTTGGACTTAAGCACCCGCCTCCTCAGATCCTCATCAAAAACACGCCTG TTCCTGCGAATCCTCCGGCAGAGTTTTCGGCTACAAAGTTTGCTTCATTCATCACC CAGTATTCCACAGGACAAGTGAGCGTGGAGATTGAATGGGAGCTGCAGAAAGAA AACAGCAAACGCTGGAATCCCGAAGTGCAGTATACATCTAACTATGCAAAATCT GCCAACGTTGATTTCACTGTGGACAACAATGGACTTTATACTGAGCCTCGCCCCA TTGGCACCCGTTACCTCACCCGTCCCCTG
>AAV6.2 capsid protein nucleic acid sequence (SEQ ID NO: 10)
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCA TTCGCGAGTGGTGGGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGC AAAAGCAGGACGACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGAC CCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCGGATGCAGCGGCCC TCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACC TGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGT CTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGAGGGTTCTCG AACCTCTTGGTCTGGTTGAGGAAGGTGCTAAGACGGCTCCTGGAAAGAAACGTC CGGTAGAGCAGTCGCCACAAGAGCCAGACTCCTCCTCGGGCATTGGCAAGACAG GCCAGCAGCCCGCTAAAAAGAGACTCAATTTTGGTCAGACTGGCGACTCAGAGT CAGTCCCCGACCCACAACCTCTCGGAGAACCTCCAGCAACCCCCGCTGCTGTGGG ACCTACTACAATGGCTTCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGG CGCCGACGGAGTGGGTAATGCCTCAGGAAATTGGCATTGCGATTCCACATGGCT GGGCGACAGAGTCATCACCACCAGCACCCGAACATGGGCCTTGCCCACCTATAA CAACCACCTCTACAAGCAAATCTCCAGTGCTTCAACGGGGGCCAGCAACGACAA CCACTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGATTTCAACAGATTCCAC TGCCATTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAATTGGGGATTCC GGCCCAAGAGACTCAACTTCAAGCTCTTCAACATCCAAGTCAAGGAGGTCACGA CGAATGATGGCGTCACGACCATCGCTAATAACCTTACCAGCACGGTTCAAGTCTT CTCGGACTCGGAGTACCAGTTGCCGTACGTCCTCGGCTCTGCGCACCAGGGCTGC CTCCCTCCGTTCCCGGCGGACGTGTTCATGATTCCGCAGTACGGCTACCTAACGC TCAACAATGGCAGCCAGGCAGTGGGACGGTCATCCTTTTACTGCCTGGAATATTT CCCATCGCAGATGCTGAGAACGGGCAATAACTTTACCTTCAGCTACACCTTCGAG GACGTGCCTTTCCACAGCAGCTACGCGCACAGCCAGAGCCTGGACCGGCTGATG AATCCTCTCATCGACCAGTACCTGTATTACCTGAACAGAACTCAGAATCAGTCCG GAAGTGCCCAAAACAAGGACTTGCTGTTTAGCCGGGGGTCTCCAGCTGGCATGTC TGTTCAGCCCAAAAACTGGCTACCTGGACCCTGTTACCGGCAGCAGCGCGTTTCT AAAACAAAAACAGACAACAACAACAGCAACTTTACCTGGACTGGTGCTTCAAAA TATAACCTTAATGGGCGTGAATCTATAATCAACCCTGGCACTGCTATGGCCTCAC ACAAAGACGACAAAGACAAGTTCTTTCCCATGAGCGGTGTCATGATTTTTGGAAA GGAGAGCGCCGGAGCTTCAAACACTGCATTGGACAATGTCATGATCACAGACGA AGAGGAAATCAAAGCCACTAACCCCGTGGCCACCGAAAGATTTGGGACTGTGGC AGTCAATCTCCAGAGCAGCAGCACAGACCCTGCGACCGGAGATGTGCATGTTAT GGGAGCCTTACCTGGAATGGTGTGGCAAGACAGAGACGTATACCTGCAGGGTCC TATTTGGGCCAAAATTCCTCACACGGATGGACACTTTCACCCGTCTCCTCTCATG GGCGGCTTTGGACTTAAGCACCCGCCTCCTCAGATCCTCATCAAAAACACGCCTG TTCCTGCGAATCCTCCGGCAGAGTTTTCGGCTACAAAGTTTGCTTCATTCATCACC CAGTATTCCACAGGACAAGTGAGCGTGGAGATTGAATGGGAGCTGCAGAAAGAA AACAGCAAACGCTGGAATCCCGAAGTGCAGTATACATCTAACTATGCAAAATCT GCCAACGTTGATTTCACTGTGGACAACAATGGACTTTATACTGAGCCTCGCCCCA TTGGCACCCGTTACCTCACCCGTCCCCTG >AAV7 capsid protein nucleic acid sequence (SEQ ID NO: 11)
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCA TTCGCGAGTGGTGGGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGC AAAAGCAGGACAACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGAC CCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCGGACGCAGCGGCCC TCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACC TGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGT CATTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCG AACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGCAAAGAAGAGAC CGGTAGAGCCGTCACCTCAGCGTTCCCCCGACTCCTCCACGGGCATCGGCAAGAA AGGCCAGCAGCCCGCCAGAAAGAGACTCAATTTCGGTCAGACTGGCGACTCAGA GTCAGTCCCCGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTAGTGTG GGATCTGGTACAGTGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAA GGTGCCGACGGAGTGGGTAATGCCTCAGGAAATTGGCATTGCGATTCCACATGG CTGGGCGACAGAGTCATTACCACCAGCACCCGAACCTGGGCCCTGCCCACCTAC AACAACCACCTCTACAAGCAAATCTCCAGTGAAACTGCAGGTAGTACCAACGAC AACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCC ACTGCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATT CCGGCCCAAGAAGCTGCGGTTCAAGCTCTTCAACATCCAGGTCAAGGAGGTCAC GACGAATGACGGCGTTACGACCATCGCTAATAACCTTACCAGCACGATTCAGGT ATTCTCGGACTCGGAATACCAGCTGCCGTACGTCCTCGGCTCTGCGCACCAGGGC TGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGCTACCTGAC TCTCAACAATGGCAGTCAGTCTGTGGGACGTTCCTCCTTCTACTGCCTGGAGTAC TTCCCCTCTCAGATGCTGAGAACGGGCAACAACTTTGAGTTCAGCTACAGCTTCG AGGACGTGCCTTTCCACAGCAGCTACGCACACAGCCAGAGCCTGGACCGGCTGA TGAATCCCCTCATCGACCAGTACTTGTACTACCTGGCCAGAACACAGAGTAACCC AGGAGGCACAGCTGGCAATCGGGAACTGCAGTTTTACCAGGGCGGGCCTTCAAC TATGGCCGAACAAGCCAAGAATTGGTTACCTGGACCTTGCTTCCGGCAACAAAG AGTCTCCAAAACGCTGGATCAAAACAACAACAGCAACTTTGCTTGGACTGGTGC CACCAAATATCACCTGAACGGCAGAAACTCGTTGGTTAATCCCGGCGTCGCCATG GCAACTCACAAGGACGACGAGGACCGCTTTTTCCCATCCAGCGGAGTCCTGATTT TTGGAAAAACTGGAGCAACTAACAAAACTACATTGGAAAATGTGTTAATGACAA ATGAAGAAGAAATTCGTCCTACTAATCCTGTAGCCACGGAAGAATACGGGATAG TCAGCAGCAACTTACAAGCGGCTAATACTGCAGCCCAGACACAAGTTGTCAACA ACCAGGGAGCCTTACCTGGCATGGTCTGGCAGAACCGGGACGTGTACCTGCAGG GTCCCATCTGGGCCAAGATTCCTCACACGGATGGCAACTTTCACCCGTCTCCTTT GATGGGCGGCTTTGGACTTAAACATCCGCCTCCTCAGATCCTGATCAAGAACACT CCCGTTCCCGCTAATCCTCCGGAGGTGTTTACTCCTGCCAAGTTTGCTTCGTTCAT CACACAGTACAGCACCGGACAAGTCAGCGTGGAAATCGAGTGGGAGCTGCAGAA GGAAAACAGCAAGCGCTGGAACCCGGAGATTCAGTACACCTCCAACTTTGAAAA GCAGACTGGTGTGGACTTTGCCGTTGACAGCCAGGGTGTTTACTCTGAGCCTCGC CCTATTGGCACTCGTTACCTCACCCGTAATCTG
>AAV8 capsid protein nucleic acid sequence (SEQ ID NO: 12)
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCA TTCGCGAGTGGTGGGCGCTGAAACCTGGAGCCCCGAAGCCCAAAGCCAACCAGC AAAAGCAGGACGACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGAC CCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCGGACGCAGCGGCCC TCGAGCACGACAAGGCCTACGACCAGCAGCTGCAGGCGGGTGACAATCCGTACC TGCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGT CTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCG AACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGAGAC CGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCGGCAAGAA AGGCCAACAGCCCGCCAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGA GTCAGTTCCAGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTG GGACCTAATACAATGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAA GGCGCCGACGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCACATGG CTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTAC AACAACCACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAAC GACAACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGAT TCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGG ATTCCGGCCCAAGAGACTCAGCTTCAAGCTCTTCAACATCCAGGTCAAGGAGGTC ACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCACCAGCACCATCCAG GTGTTTACGGACTCGGAGTACCAGCTGCCGTACGTTCTCGGCTCTGCCCACCAGG GCTGCCTGCCTCCGTTCCCGGCGGACGTGTTCATGATTCCCCAGTACGGCTACCT AACACTCAACAACGGTAGTCAGGCCGTGGGACGCTCCTCCTTCTACTGCCTGGAA TACTTTCCTTCGCAGATGCTGAGAACCGGCAACAACTTCCAGTTTACTTACACCTT CGAGGACGTGCCTTTCCACAGCAGCTACGCCCACAGCCAGAGCTTGGACCGGCT GATGAATCCTCTGATTGACCAGTACCTGTACTACTTGTCTCGGACTCAAACAACA GGAGGCACGGCAAATACGCAGACTCTGGGCTTCAGCCAAGGTGGGCCTAATACA ATGGCCAATCAGGCAAAGAACTGGCTGCCAGGACCCTGTTACCGCCAACAACGC GTCTCAACGACAACCGGGCAAAACAACAATAGCAACTTTGCCTGGACTGCTGGG ACCAAATACCATCTGAATGGAAGAAATTCATTGGCTAATCCTGGCATCGCTATGG CAACACACAAAGACGACGAGGAGCGTTTTTTTCCCAGTAACGGGATCCTGATTTT TGGCAAACAAAATGCTGCCAGAGACAATGCGGATTACAGCGATGTCATGCTCAC CAGCGAGGAAGAAATCAAAACCACTAACCCTGTGGCTACAGAGGAATACGGTAT CGTGGCAGATAACTTGCAGCAGCAAAACACGGCTCCTCAAATTGGAACTGTCAA CAGCCAGGGGGCCTTACCCGGTATGGTCTGGCAGAACCGGGACGTGTACCTGCA GGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCACCCGTCTCCG CTGATGGGCGGCTTTGGCCTGAAACATCCTCCGCCTCAGATCCTGATCAAGAACA CGCCTGTACCTGCGGATCCTCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTT CATCACGCAATACAGCACCGGACAGGTCAGCGTGGAAATTGAATGGGAGCTGCA GAAGGAAAACAGCAAGCGCTGGAACCCCGAGATCCAGTACACCTCCAACTACTA CAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCGTGTACTCTGAACCC CGCCCCATTGGCACCCGTTACCTCACCCGTAATCTG
>AAV9 capsid protein nucleic acid sequence (SEQ ID NO: 13)
ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTTAGTGAAGGAA TTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAGGCAAATCAAC AACATCAAGACAACGCTCGAGGTCTTGTGCTTCCGGGTTACAAATACCTTGGACC CGGCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCC TCGAGCACGACAAGGCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACC TCAAGTACAACCACGCCGACGCCGAGTTCCAGGAGCGGCTCAAAGAAGATACGT CTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAAAAGAGGCTTCTTGA ACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACGGCTCCTGGAAAGAAGAGGCC TGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGT GCACAGCCCGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCA GTCCCAGACCCTCAACCAATCGGAGAACCTCCCGCAGCCCCCTCAGGTGTGGGAT CTCTTACAATGGCTTCAGGTGGTGGCGCACCAGTGGCAGACAATAACGAAGGTG CCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCAATGGCTGGG GGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAA TCACCTCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAAC GCCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACT GCCACTTCTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCG GCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTCAAAGAGGTTACGGAC AACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTC ACGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCC TCCCGCCGTTCCCAGCGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTT AATGATGGAAGCCAGGCCGTGGGTCGTTCGTCCTTTTACTGCCTGGAATATTTCC CGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCAGCTACGAGTTTGAGA ACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATGAA TCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGA CAGAATCAACAAACGCTAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTC CAGGGAAGAAACTACATACCTGGACCCAGCTACCGACAACAACGTGTCTCAACC ACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCCTGGAGCTTCTTCTTGGG CTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCACAA AGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAA GGAACTGGAAGAGACAACGTGGATGCGGACAAAGTCATGATAACCAACGAAGA AGAAATTAAAACTACTAACCCGGTAGCAACGGAGTCCTATGGACAAGTGGCCAC AAACCACCAGAGTGCCCAAGCACAGGCGCAGACCGGCTGGGTTCAAAACCAAGG AATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGACCCATT TGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAG GGTTTGGAATGAAGCACCCGCCTCCTCAGATCCTCATCAAAAACACACCTGTACC TGCGGATCCTCCAACGGCCTTCAACAAGGACAAGCTGAACTCTTTCATCACCCAG TATTCTACTGGCCAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAAAAC AGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTACAAGTCTAAT AATGTTGAATTTGCTGTTAATACTGAAGGTGTATATAGTGAACCCCGCCCCATTG GCACCAGATACCTGACTCGTAATCTG
>AAVrh. lO capsid protein nucleic acid sequence (SEQ ID NO: 14)
TCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGACTTGAAACCTGGAG CCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGGTGC TTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGT CAACGCGGCGGACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCT CAAAGCGGGTGACAATCCGTACCTGCGGTATAACCACGCCGACGCCGAGTTTCA GGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTT CCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAA GACGGCTCCTGGAAAGAAGAGACCGGTAGAGCCATCACCCCAGCGTTCTCCAGA CTCCTCTACGGGCATCGGCAAGAAAGGCCAGCAGCCCGCGAAAAAGAGACTCAA CTTTGGGCAGACTGGCGACTCAGAGTCAGTGCCCGACCCTCAACCAATCGGAGA ACCCCCCGCAGGCCCCTCTGGTCTGGGATCTGGTACAATGGCTGCAGGCGGTGGC GCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCAGGA AATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCC GAACCTGGGCCCTCCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGG GACTTCGGGAGGAAGCACCAACGACAACACCTACTTCGGCTACAGCACCCCCTG GGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAG CGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAACTTCAAGCTCT TCAACATCCAGGTCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCA ATAACCTTACCAGCACGATTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTA CGTCCTCGGCTCTGCGCACCAGGGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTC ATGATTCCTCAGTACGGGTACCTGACTCTGAACAATGGCAGTCAGGCCGTGGGCC GTTCCTCCTTCTACTGCCTGGAGTACTTTCCTTCTCAAATGCTGAGAACGGGCAAC AACTTTGAGTTCAGCTACCAGTTTGAGGACGTGCCTTTTCACAGCAGCTACGCGC ACAGCCAAAGCCTGGACCGGCTGATGAACCCCCTCATCGACCAGTACCTGTACTA CCTGTCTCGGACTCAGTCCACGGGAGGTACCGCAGGAACTCAGCAGTTGCTATTT TCTCAGGCCGGGCCTAATAACATGTCGGCTCAGGCCAAAAACTGGCTACCCGGG CCCTGCTACCGGCAGCAACGCGTCTCCACGACACTGTCGCAAAATAACAACAGC AACTTTGCCTGGACCGGTGCCACCAAGTATCATCTGAATGGCAGAGACTCTCTGG TAAATCCCGGTGTCGCTATGGCAACCCACAAGGACGACGAAGAGCGATTTTTTCC GTCCAGCGGAGTCTTAATGTTTGGGAAACAGGGAGCTGGAAAAGACAACGTGGA CTATAGCAGCGTTATGCTAACCAGTGAGGAAGAAATTAAAACCACCAACCCAGT GGCCACAGAACAGTACGGCGTGGTGGCCGATAACCTGCAACAGCAAAACGCCGC TCCTATTGTAGGGGCCGTCAACAGTCAAGGAGCCTTACCTGGCATGGTCTGGCAG AACCGGGACGTGTACCTGCAGGGTCCTATCTGGGCCAAGATTCCTCACACGGAC GGAAACTTTCATCCCTCGCCGCTGATGGGAGGCTTTGGACTGAAACACCCGCCTC CTCAGATCCTGATTAAGAATACACCTGTTCCCGCGGATCCTCCAACTACCTTCAG TCAAGCTAAGCTGGCGTCGTTCATCACGCAGTACAGCACCGGACAGGTCAGCGT GGAAATTGAATGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAACCCAGAGA TTCAATACACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTTAACAC AGATGGCACTTATTCTGAGCCTCGCCCCATCGGCACCCGTTACCTCACCCGTAAT CTGTAATTGCTTGTTAATCAATAAACCGGTTGATTCGTTTCAGTTGAACTTTGGTC TCTGCGAAGGGCGAATTCGTTT >miR34a nucleic acid sequence (SEQ ID NO 15)
AGGAATTCTGCTGGAGGAGTGTGTCATACCTCGGTAGGGTCCACTACACATCTTT CTCCCGCAGCCTCTCCATCTTCCTGTGACTGCGGGCGCCTCAGCCTGGGCTGGCC AGCTGTGAGTAATTCTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGTATTAGCTAA GGAAGCAATCAGCAAGTATACTGCCCTAGAAGTGCTGCACATTGTTGGGCCGAG AAGGAAAAGGTCAGAGGTCAGCAACGCCCACACCCCTGAGAGGCGCTGGACTTG CGGAGCTGCTCGACCATACTGGTGGGTATGGGATGGCGGCCGCGTCCC
> miR34a-Gluc expression construct nucleic acid sequence (SEQ ID NO: 16)
CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCG ACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGTAG CCATGCTCTAGGAAGATCAATTCGGTACAATTCACGCGTCGACATTGATTATTGA CTCTGGTCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGA CCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGA CTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT ACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAA TGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGC AGTACATCTACTCGAGGCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCC CACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCG GGGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGG CGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCT CCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCG AAGCGCGCGGCGGGCGGGAGCGGGATCAGCCACCGCGGTGGCGGCCCTAGAGTC GATCGAGGAACTGAAAAACCAGAAAGTTAACTGGTAAGTTTAGTCTTTTTGTCTT TTATTTCAGGAATTCTGCTGGAGGAGTGTGTCATACCTCGGTAGGGTCCACTACA CATCTTTCTCCCGCAGCCTCTCCATCTTCCTGTGACTGCGGGCGCCTCAGCCTGGG CTGGCCAGCTGTGAGTAATTCTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGTATTA GCTAAGGAAGCAATCAGCAAGTATACTGCCCTAGAAGTGCTGCACATTGTTGGG CCGAGAAGGAAAAGGTCAGAGGTCAGCAACGCCCACACCCCTGAGAGGCGCTG GACTTGCGGAGCTGCTCGACCATACTGGTGGGTATGGGATGGCGGCCGCGTCCC GGATCCGGTGGTGGTGCAAATCAAAGAACTGCTCCTCAGTGGATGTTGCCTTTAC TTCTAGGCCTGTACGGAAGTGTTACTTCTGCTCTAAAAGCTGCGGAATTGTACCC GCGGCCGATCCACCGGTCGCCACCATCTAGCATGGGAGTCAAAGTTCTGTTTGCC CTGATCTGCATCGCTGTGGCCGAGGCCAAGCCCACCGAGAACAACGAAGACTTC AACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGC GGGAAGTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGATGGAAGCC AATGCCCGGAAAGCTGGCTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCA AGTGCACGCCCAAGATGAAGAAGTTCATCCCAGGACGCTGCCACACCTACGAAG GCGACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCGTCGACATTCCTG AGATTCCTGGGTTCAAGGACTTGGAGCCCATGGAGCAGTTCATCGCACAGGTCG ATCTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTG TTCTGACCTGCTCAAGAAGTGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAG ATCCAGGGCCAGGTGGACAAGATCAAGGGGGCCGGTGGTGACTAGCTCGACGCT GATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCC GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATG AGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGT GGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATTAGGTAGATAAGTAGC ATGGCGGGTTAATCATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCC CTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGC CCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAG
EXAMPLES
Example 1. Adeno-associated virus serotype vectors efficiently transduce normal prostate tissue and prostate cancer cells
This example describes the unexpected result that certain serotypes of AAV vectors mediate highly efficient transduction in prostate tissue (e.g., mouse prostate tissue), which may be useful for performing mechanistic studies and gene therapy for prostate diseases, such as prostate cancer, in subjects such as dogs, monkeys, and humans (see, for example, Martijn
C. Nawijn et al. European Urology Supplements, 7, 566-575, 2008 and Cory Abate-Shen, et al. Trends in Genetics. 18 (5):S 1-S5, 2002). It was previously shown that intraperitoneal (i.p.) injection of certain rAAV serotypes such as rAAV8 into WT mice could transduce tissues surrounding the peritoneal cavity such as the diaphragm, but prostate transduction has not been reported to the best of Applicants' knowledge. To screen for rAAV serotypes that efficiently transduce mouse prostate in vivo, i.p. injection of 12 serotypes of enhanced green fluorescent protein (EGFP)-expressing rAAV vectors was performed in WT C57BL/6 male mice, including rAAV2, 3b, 5, 6, 6.2, 7, 8, 9, rh.8, rh. l0, rh.39 and rh.43.
EGFP fluorescence signal was barely observed in the prostate tissue sections three weeks after vector injection, indicating inefficient transduction. Next, the same panel of rAAV vectors was injected directly into mouse prostate. The mouse prostate is divided into anterior prostate (AP) that contains two lobes and dorsal lateral prostate (DLP) (FIG. 1). rAAV vectors were thus injected into four sites per prostate, namely the two lobes of AP and two sites of DLP (FIG. 1).
Three weeks after injection, AP and DLP cryo-sections were subjected to
fluorescence microscopy. It was found that rAAV6.2, rAAV7 and rAAV9 outperformed the other serotypes in transducing AP (FIGs. 2A-2B, FIG. 4A). Among these three serotypes, rAAV6.2 and rAAV7 also transduced DLP efficiently (FIGs. 3A-3B, FIG. 4A). In addition, rAAV5, rAAV8 and rAAVrh.10 transduced DLP (FIG. 3A, FIG. 4A). For the two leading serotypes that transduced both AP and DLP (rAAV6.2 and rAAV7), the vector genome biodistribution in the injected AP and DLP was determined to be approximately 10-20 rAAV genome copies per cell (FIG. 4B). Normal histology was observed by H&E staining in both AP and DLP, without indication of inflammation or other adverse effects following PBS or rAAV injection (FIG. 5). These results suggested that rAAV6.2 and rAAV7 are good candidates for efficient and safe delivery of genes of interest to mouse prostate in vivo.
To further characterize the prostatic cell types that were transduced with rAAV6.2 and rAAV7, immunofluorescence staining of mouse AP and DLP sections was performed with antibodies against cellular markers of major prostate cell types including luminal cells (K8), basal cells (K5) and stromal cells (a-actin for smooth muscle cells). It was found that both serotypes were able to transduce the majority of the three cell types in both AP and DLP. Representative fluorescence microscopic images are shown in FIG. 6A. Quantification of EGFP-positive cells of each cell type revealed that 65-80% of luminal cells, basal cells and stromal cells could be transduced (FIG. 6B). Example 2. rAAV-based and intraprostatically delivered miR-34a therapeutics or efficient inhibition of prostate cancer progression
Prostate cancer (PCa) is the second most common diagnosed cancer and the fifth cause of cancer-related mortality for males worldwide. At present, there is no effective treatment for PCa. Towards further understanding molecular mechanism and developing therapeutics for PCa, the role of miR34a in PCa progression was investigated.
Expression of miR-34a is significantly downregulated in PCa cells. Here, downregulation of miR34a in prostate tumor from transgenic adenocarcinoma mouse prostate (TRAMP) model was examined. Relative expression of miR34a in prostate tissue of wild type and TRAMP mice was quantified by quantitative PCR (qPCR). Results demonstrate that expression of miR34a is significantly downregulated in the TRAMP mice (FIG. 7A). An rAAV-pri-miR34a construct was produced and tested using a luciferase assay. Results indicate that the rAAV-pir-miR34a construct efficiently downregulates expression of the reporter gene {e.g., luciferase) (FIG. 7B) in vitro. Analysis by qPCR demonstrates that miR34a overexpression inhibits growth of prostate cancer cells (FIG. 8A). In particular, it was found that overexpression of miR-34a significantly inhibits the cell cycle of PC3 cells (FIG. 8B) by prolonging Gi (FIG. 8C-8D)and shortening S phases through targeting cyclin Dl (CCND1), CD44, and DNA topoisomerase 2-alpha (TOP 2 A), as shown in FIG. 8E. It was also observed that miR34a overexpression reduces cell viability (FIGs. 9A-9B) and inhibits cell migration of PC3 cells as measured by a wound healing assay (FIG. 9C-9D).
To investigate if in vivo gene delivery of pri-miR34a to the prostates of TRAMP mice can inhibit PCa progression, 12 serotypes of rAAVs were screened for efficient prostate targeting in vivo and in PCa cells in vitro. Several candidate vectors (e.g., AAV6.2, AAV7 and AAV9) were identified. Intraprostatic injection of rAAV9-pri -miR34a (4xlOn
GCs/prostate) to 8-week old TRAMP mice for inhibition of PCa progression was
investigated. Treatment with rAAV7-miR34a lowered body weights significantly (p < 0.05) as compared to the control group starting from 24 weeks after injection, likely a result of the higher tumor burden in the control group (FIG. 10A). rAAV7-miR34a treatment also significantly extended the lifespan of TRAMP mice (p < 0.05) (FIG. 10B). Moreover, proliferation and neoplasia in the rAAV7-mir34a treated prostates were significantly diminished in both the anterior prostate (AP) and dorsal lateral prostate (DLP) when compared to those in the control group (FIG. 11).
Longevity of miR34a expression was also investigated. miRNA and reporter expression in mouse prostate were measured by qPCR and reporter (Glue) assay 3 weeks post intrapro static injection. Results indicate that miR34 expression is highly upregulated in treated mice versus control mice (FIG. 12A) and that miR34 expression persists for up to 52 weeks after injection (FIG. 12B). It was also observed that expression of Aldolase A, Fructose-Bisphosphate (ALDOA) and Sex Determining Region Y)-Box 4 (Sox4) were significantly downregulated in miR34a-treated mouse prostate compared to untreated control mouse prostate (FIG. 12C). Relative protein expression results were confirmed by Western blot, which show miR34a overexpression downregulates ALDOA, Ccndl, and Sox4 expression in mouse prostate (FIG. 13).
In sum, these results demonstrate the potential of rAAV-mediated efficient modulation of miRNA expression in the prostate for inhibiting PCa progression.

Claims

CLAIMS What is claimed is:
1. A method for delivering a transgene to prostate tissue, the method comprising:
administering to prostate tissue of a subject an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh. lO, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
2. The method of claim 1, wherein the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7.
3. The method of claim 1 or 2, wherein the capsid protein comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
4. The method of any one of claims 1 to 3, wherein the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
5. The method of any one of claims 1 to 4, wherein the transgene encodes a gene associated with a prostate disease.
6. The method of claim 5, wherein the prostate disease is selected from prostatitis, prostate cancer and benign prostate hyperplasia (BPH).
7. The method of claim 5 or 6, wherein the gene encodes a gene selected from the group consisting of BCL-2, PTEN, SLC39A1, BRCAl, BRCA2, HPCl, RUNX2, CLCA2, YAPl, MASPIN, LL37, CDKN1B, AR, NKX3.1, CASP9, FKHR, GSK3, MDM2, ERK1/2, PSA,CCND1, ALDOA, Sox4, CD44, and miR34a.
8. The method of any one of claims 1 to 7, wherein the administration occurs by injection.
9. The method of claim 8, wherein the injection is not intraperitoneal injection (i.p.).
10. The method of claim 8 or 9, wherein the injection is intraprostate injection.
11. The method of any one of claims 1 to 10, wherein the administration results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells.
12. The method of claim 11, wherein the administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
13. The method of any one of claims 1 to 12, wherein the rAAV further comprises two AAV inverted terminal repeats (ITRs), wherein the ITRs flank the transgene.
14. The method of claim 13, wherein the AAV ITRs are ITRs of one or more serotypes selected from: AAV2, AAV3, AAV4, AAV5, and AAV6.
15. The method of any one of claims 1 to 14, wherein the subject is a mammal, optionally a human.
16. A method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of rAAV, wherein the rAAV comprises (i) a capsid protein having a serotype selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and AAVrh.10, and (ii) a nucleic acid comprising a promoter operably linked to a transgene.
17. The method of claim 16, wherein the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7.
18. The method of claim 16 or 17, wherein the capsid protein comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
19. The method of any one of claims 16 to 18, wherein the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
20. The method of any one of claims 16 to 19, wherein the transgene encodes a gene associated with a prostate disease.
21. The method of claim 20, wherein the prostate disease is selected from prostatitis, prostate cancer and benign prostate hyperplasia (BPH).
22. The method of claim 20 or 21, wherein the gene encodes a gene selected from the group consisting of BCL-2, PTEN, SLC39A1, BRCAl, BRCA2, HPCl, RUNX2, CLCA2, YAPl, MASPIN, LL37, CDKNIB, AR, NKX3.1, CASP9, FKHR, GSK3, MDM2, ERKl/2, PSA, CCND1, ALDOA, CD44, Sox4, and miR34a.
23. The method of any one of claims 16 to 22, wherein the administration occurs by injection.
24. The method of claim 23, wherein the injection is not intraperitoneal injection (i.p.).
25. The method of claim 23 or 24, wherein the injection is intraprostate injection.
26. The method of any one of claims 16 to 25, wherein the administration results in transduction of a prostate cell type selected from the group consisting of luminal prostate cells, basal prostate cells, and stromal prostate cells.
27. The method of claim 26, wherein the administration results in transduction of at least two of the following prostate cell types: luminal prostate cells, basal prostate cells, and stromal prostate cells.
28. The method of any one of claims 16 to 27, wherein the rAAV further comprises two AAV inverted terminal repeats (ITRs), wherein the ITRs flank the transgene.
29. The method of claim 28, wherein the AAV ITRs are ITRs of one or more serotypes selected from: AAV2, AAV3, AAV4, AAV5, and AAV6.
30. The method of any one of claims 16 to 29, wherein the subject is a mammal, optionally a human.
31. A method for treating a prostate disease, the method comprising: administering to a subject having or suspected of having a prostate disease an effective amount of a nucleic acid comprising a promoter operably linked to a transgene, wherein the transgene encodes miR34a.
32. The method of claim 31, wherein the transgene comprises the sequence set forth in SEQ ID NO: 15.
33. The method of claim 31 or 32, wherein the transgene is flanked by adeno-associated virus inverted terminal repeats (AAV ITRs).
34. The method of any one of claims 31 to 33, wherein the transgene further comprises a nucleic acid sequence encoding a reporter gene, optionally luciferase.
35. The method of any one of claims 31 to 34, wherein the transgene comprises the sequence set forth in SEQ ID NO: 16.
36. The method of any one of claims 31 to 35, wherein the nucleic acid is in a recombinant adeno-associated virus (rAAV).
37. The method of claim 36, wherein the rAAV comprises at least one capsid protein selected from the group consisting of AAV5, AAV6.2, AAV7, AAV8, AAV9, and
AAVrh.10.
38. The method of claim 37, wherein the capsid protein comprises an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95% , or at least 99% identical to any one of SEQ ID NO: 1-7.
39. The method of claim 37 or 38, wherein the at least one capsid protein comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
40. The method of any one of claims 37 to 39, wherein the capsid protein is AAV6.2 capsid protein (SEQ ID NO: 3) or AAV7 capsid protein (SEQ ID NO: 4).
41. The method of any one of claims 31 to 40, wherein the administration occurs by injection.
42. The method of claim 41, wherein the injection is not intraperitoneal injection (i.p.).
43. The method of claim 41 or 42, wherein the injection is intraprostate injection.
44. The method of any one of claims 31 to 43, wherein the subject is a human.
PCT/US2016/058185 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors WO2017070516A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3002980A CA3002980A1 (en) 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors
EP16858324.3A EP3364996B1 (en) 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors
US15/769,953 US11426469B2 (en) 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors
US17/813,451 US20230073187A1 (en) 2015-10-22 2022-07-19 Prostate targeting adeno-associated virus serotype vectors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245027P 2015-10-22 2015-10-22
US62/245,027 2015-10-22
US201662322285P 2016-04-14 2016-04-14
US62/322,285 2016-04-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/769,953 A-371-Of-International US11426469B2 (en) 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors
US17/813,451 Continuation US20230073187A1 (en) 2015-10-22 2022-07-19 Prostate targeting adeno-associated virus serotype vectors

Publications (1)

Publication Number Publication Date
WO2017070516A1 true WO2017070516A1 (en) 2017-04-27

Family

ID=58557883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/058185 WO2017070516A1 (en) 2015-10-22 2016-10-21 Prostate-targeting adeno-associated virus serotype vectors

Country Status (4)

Country Link
US (2) US11426469B2 (en)
EP (1) EP3364996B1 (en)
CA (1) CA3002980A1 (en)
WO (1) WO2017070516A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
US10570395B2 (en) 2014-11-14 2020-02-25 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US10745447B2 (en) 2015-09-28 2020-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
CN111778281A (en) * 2020-07-17 2020-10-16 四川省人民医院 Construction method and application of retina bipolar cytopathy model
US20210217041A1 (en) * 2018-04-04 2021-07-15 Capital One Services, Llc User recognition based user experience platform
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11759506B2 (en) 2017-06-15 2023-09-19 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
US11931375B2 (en) 2017-10-16 2024-03-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
US11976096B2 (en) 2018-04-03 2024-05-07 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US11981914B2 (en) 2019-03-21 2024-05-14 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
US12060390B2 (en) 2018-04-03 2024-08-13 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
US12116384B2 (en) 2018-04-03 2024-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
US12123002B2 (en) 2022-12-20 2024-10-22 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
GB201914296D0 (en) * 2019-10-03 2019-11-20 Univ Oxford Innovation Ltd Treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033321A2 (en) * 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
WO2008154333A2 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
US20100227909A1 (en) * 2007-05-03 2010-09-09 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer
EP2468891A2 (en) * 2006-01-05 2012-06-27 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
ATE402254T1 (en) 1998-05-28 2008-08-15 Us Gov Health & Human Serv AAV5 VECTORS AND THEIR USE
US20030110526A1 (en) 1998-08-25 2003-06-12 Robert H. Brown Dysferlin mutations
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001027256A2 (en) * 1999-10-14 2001-04-19 The Regents Of The University Of California System Chimeric transcriptional regulatory element and methods for prostate-targeted gene expression
US6544786B1 (en) 1999-10-15 2003-04-08 University Of Pittsburgh Of The Commonwealth Of Higher Education Method and vector for producing and transferring trans-spliced peptides
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
US6962815B2 (en) 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US20030103939A1 (en) 2001-07-13 2003-06-05 Engelhardt John F. Pseudotyped adeno-associated viruses and uses thereof
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
NZ578982A (en) 2001-11-13 2011-03-31 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
JP4769417B2 (en) 2001-12-17 2011-09-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Adeno-associated virus (AAV) serotype 9 sequences, vectors containing the same and uses thereof
ES2975413T3 (en) 2001-12-17 2024-07-05 Univ Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors that contain them and their uses
WO2003089612A2 (en) 2002-04-17 2003-10-30 University Of Florida Research Foundation, Inc. IMPROVED rAAV VECTORS
AU2003221745A1 (en) 2002-04-19 2003-11-03 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
JP3943048B2 (en) 2002-04-29 2007-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Method for direct rescue and amplification of integrated virus from cellular DNA of tissue
US20060093589A1 (en) 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
EP2522723B1 (en) 2003-01-28 2014-12-03 Cellectis Custom-made meganuclease and use thereof
US7387896B2 (en) 2003-03-26 2008-06-17 The Regents Of The University Of Michigan MicroRNA vectors
WO2004108922A2 (en) * 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
US20060228800A1 (en) 2003-05-15 2006-10-12 Shi-Lung Lin Novel Transgenic Methods Using intronic RNA
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
EP2363483A3 (en) 2004-03-05 2014-07-16 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAi agents
US7498316B2 (en) 2004-04-06 2009-03-03 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using RNA interference
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
EP1877556B1 (en) 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2799547B1 (en) 2006-11-08 2016-12-21 Veritas Bio, LLC In Vivo Delivery of RNA to a Target Cell
ES2714007T3 (en) 2007-04-09 2019-05-24 Univ Florida Compositions of rAAV vectors that have tyrosine modified capsid proteins and methods for their use
ES2907452T3 (en) 2007-04-12 2022-04-25 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Genetic deletion and replacement
US8258286B2 (en) 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2009079592A2 (en) 2007-12-17 2009-06-25 California Institute Of Technology Modulating immune system development and function through microrna mir-146
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
WO2009146178A1 (en) 2008-04-15 2009-12-03 President And Fellows Of Harvard College Angiogenin and amyotrophic lateral sclerosis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
US20110171262A1 (en) 2008-06-17 2011-07-14 Andrew Christian Bakker Parvoviral capsid with incorporated gly-ala repeat region
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst Methods and compositions for modulating angiogenesis
EP2329275A2 (en) 2008-09-04 2011-06-08 Galenea Corporation Synaptic vesicle cycling assays and systems
WO2010071454A1 (en) 2008-12-17 2010-06-24 Auckland Uniservices Limited Adeno-associated viral vectors and uses thereof
WO2010099383A2 (en) 2009-02-26 2010-09-02 The Johns Hopkins University Compositions and methods for ex vivo hepatic nucleic acid delivery
CA2759801C (en) 2009-05-02 2019-04-02 Marco A. Passini Gene therapy for neurodegenerative disorders
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2261242A1 (en) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
US20120270930A1 (en) 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
BR112012010866A2 (en) 2009-11-09 2016-11-29 Genepod Therapeutics Ab "New viral vector construct for continuous optimized specific synthesis of dopa by neurons in vivo."
US9493776B2 (en) 2009-11-19 2016-11-15 National University Corporation Okayama University System for increasing gene expression and vector comprising the system
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
AU2011209743B2 (en) 2010-01-28 2016-03-10 The Children's Hospital Of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
AU2011223820B2 (en) 2010-03-01 2016-01-14 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the HCV genome
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
US8785413B2 (en) 2010-09-27 2014-07-22 Florida Atlantic University Research Corporation Materials and methods for the treatment of pathological neovascularization in the eye
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
HUE043921T2 (en) 2011-02-17 2019-09-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
EP2699258A4 (en) 2011-04-15 2014-10-29 Us Sec Dep Of Health And Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
ES2661680T3 (en) 2011-04-21 2018-04-03 University Of Massachusetts Compositions based on VAAr and methods for treating alpha-1 anti-trypsin deficiencies
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10184151B2 (en) 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
US20130142861A1 (en) 2011-12-05 2013-06-06 National Yang Ming University Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis
ES2752191T3 (en) 2012-02-17 2020-04-03 Childrens Hospital Philadelphia Compositions and methods with AAV vectors for gene transfer to cells, organs and tissues
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
SG11201504523UA (en) 2012-12-12 2015-07-30 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CA2897932A1 (en) 2013-01-14 2014-07-17 Recombinetics, Inc. Hornless livestock
JP2016514152A (en) 2013-03-13 2016-05-19 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Adeno-associated virus vector and method of use thereof
AU2014227766B2 (en) 2013-03-15 2018-10-04 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
US10494645B2 (en) 2013-04-18 2019-12-03 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
WO2014186746A1 (en) 2013-05-16 2014-11-20 University Of Florida Research Foundation, Inc. HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
EP3004370B1 (en) 2013-06-05 2024-08-21 Duke University Rna-guided gene editing and gene regulation
CA2915842C (en) 2013-06-17 2022-11-29 The Broad Institute, Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
US10155794B2 (en) 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
WO2015020522A1 (en) 2013-08-05 2015-02-12 Koninklijke Nederlandse Akademie Van Wetenschappen Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp
ES2799437T3 (en) 2013-08-27 2020-12-17 The Res Institute At Nationwide Childrens Hospital Products and methods for the treatment of amyotrophic lateral sclerosis
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
EP3119892B1 (en) 2014-03-17 2021-03-10 The Hospital For Sick Children Beta-hexosaminidase protein variants and associated methods for treating gm2 gangliosdoses
EP4410805A2 (en) 2014-03-18 2024-08-07 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
HUE054768T2 (en) 2014-05-02 2021-09-28 Genzyme Corp Aav vectors for retinal and cns gene therapy
CN107075514A (en) 2014-05-20 2017-08-18 衣阿华大学研究基金会 The therapeutic compounds of Huntington's disease
EP3209311B1 (en) 2014-10-21 2024-03-06 University of Massachusetts Recombinant aav variants and uses thereof
WO2017023724A1 (en) 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033321A2 (en) * 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP2468891A2 (en) * 2006-01-05 2012-06-27 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US20100227909A1 (en) * 2007-05-03 2010-09-09 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer
WO2008154333A2 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIORINI, JA ET AL.: "Cloning and Characterization of Adeno-Associated Virus Type 5.", JOURNAL OF VIROLOGY., vol. 73, no. 2, February 1999 (1999-02-01), pages 1309 - 1319, XP002125035 *
See also references of EP3364996A4 *
TARASOV, V ET AL.: "Differential Regulation of microRNAs by p53 Revealed by massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest.", CELL CYCLE., vol. 6, no. 13, 1 July 2007 (2007-07-01), pages 1586 - 1593, XP002535302 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US11027000B2 (en) 2014-11-05 2021-06-08 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US11975056B2 (en) 2014-11-05 2024-05-07 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
US11542506B2 (en) 2014-11-14 2023-01-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US10920227B2 (en) 2014-11-14 2021-02-16 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US12071625B2 (en) 2014-11-14 2024-08-27 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10570395B2 (en) 2014-11-14 2020-02-25 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11198873B2 (en) 2014-11-14 2021-12-14 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US11840555B2 (en) 2015-09-28 2023-12-12 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US10745447B2 (en) 2015-09-28 2020-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11208438B2 (en) 2015-09-28 2021-12-28 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11193129B2 (en) 2016-05-18 2021-12-07 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US12084659B2 (en) 2016-05-18 2024-09-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11759506B2 (en) 2017-06-15 2023-09-19 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US12116589B2 (en) 2017-10-16 2024-10-15 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11931375B2 (en) 2017-10-16 2024-03-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US12060390B2 (en) 2018-04-03 2024-08-13 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US11976096B2 (en) 2018-04-03 2024-05-07 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12116384B2 (en) 2018-04-03 2024-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
US11810143B2 (en) * 2018-04-04 2023-11-07 Capital One Services, Llc User recognition based user experience platform
US20210217041A1 (en) * 2018-04-04 2021-07-15 Capital One Services, Llc User recognition based user experience platform
US11981914B2 (en) 2019-03-21 2024-05-14 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
CN111778281B (en) * 2020-07-17 2021-04-23 四川省人民医院 Construction method and application of retina bipolar cytopathy model
CN111778281A (en) * 2020-07-17 2020-10-16 四川省人民医院 Construction method and application of retina bipolar cytopathy model
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
US12123002B2 (en) 2022-12-20 2024-10-22 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
US20230073187A1 (en) 2023-03-09
EP3364996A4 (en) 2019-06-12
CA3002980A1 (en) 2017-04-27
US11426469B2 (en) 2022-08-30
EP3364996B1 (en) 2021-08-25
US20180311380A1 (en) 2018-11-01
EP3364996A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
US20230073187A1 (en) Prostate targeting adeno-associated virus serotype vectors
US11920168B2 (en) Compositions and methods for transient delivery of nucleases
AU2023200880B2 (en) Minigene therapy
US20220162570A1 (en) Aav-mediated gene therapy for maple syrup urine disease (msud)
US20220185862A1 (en) Dna-binding domain transactivators and uses thereof
WO2023147584A2 (en) Compositions and methods for treating sialidosis
EP3794125A1 (en) Modified aav constructs and uses thereof
US20230340470A1 (en) Methods for treating huntington&#39;s disease
US20240207370A1 (en) Gene therapy for bcaa modulation in maple syrup urine disease (msud)
US20230279405A1 (en) Dna-binding domain transactivators and uses thereof
EA047753B1 (en) DNA-BINDING DOMAIN TRANSACTIVATORS AND THEIR APPLICATIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16858324

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3002980

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016858324

Country of ref document: EP